Data shows how athletes logged activities on two legs and two wheels
, /PRNewswire/ -- Garmin (NYSE: GRMN) is celebrating both global running day and global cycling day with the release of its running and cycling data reports, highlighting how athletes around the world are recording runs and rides. Whether taking to the trails, roads, mountainsides or their home gyms, the Garmin Connect™ community proved running and cycling activities remain popular globally.
Here are some key takeaways from the past year:
Garmin's running and cycling data reports highlight how athletes around the world are recording runs and rides. Running data
Garmin runners recorded nearly 13% more indoor and 3% more outdoor running activities. There was also a 23% increase in users who recorded a run and a strength activity in the same week. The average distance ran was 4.82 miles with those aged 50-59 running slightly more per activity on average at 5.1 miles. The average pace per mile was 9:21 for men and 10:11 for women. Runners in Ireland logged the fastest average mile (9:09) followed by those in Portugal and then Italy. Runners logged the most miles in August and typically ran the farthest on Saturdays. The half marathon training plan was the most popular distance trained for using Garmin Coach. The average VO2 max for all Garmin runners was 50 and the average sleep score was 73. Cycling data
The average bike ride per user was 28.59 miles with cyclists in Italy recording the highest average miles per ride (34.73), followed by those in Belgium and then Spain. Garmin cyclists spent about 115 minutes on average on each ride. They also recorded most of their rides on Sundays and the most popular month of the year for all rides was August. Garmin cyclists rode an average speed of 14.89 miles per hour (mph) and climbed an average 1,158 feet per ride. The average VO2 max for all Garmin cyclists was 51. Data also indicates that the more miles cyclists recorded each week, the higher their VO2 max was. Click here to read the entire running data report and here to read the cycling data report.
What athletes love about Garmin
"Living in Seattle, I rely heavily on indoor track training, and the indoor track activity on my Garmin Forerunner® 970 allows me to maintain the same level of pacing precision I expect from GPS outdoors. The consistency my smartwatch provides is critical for getting the most out of every session—no matter where I'm running."
—Isaiah Harris, Garmin-sponsored 800m runner
"My Edge 850 is a non-negotiable for every training ride. Lately, I have been exploring new ride areas and trails. It's so important for me to reduce my pause time while training, so I have a screen set on my Edge with a large view of navigation with a couple ride stats, including my ride time and power. Since the navigation on the Edge is so easy to use and read while riding, I can stay on top of my specific training plan and ride like a local in new places. The entire ecosystem on Garmin Connect makes it easy to view my training stats, sleep, and recovery all in one place. One feature I really appreciate is the Altitude Acclimation, which allows me to track my elevation and performance improvements throughout my altitude training. Since I am tracking my training load on my Edge and sleep with my Index™ Sleep Monitor1, I can optimally observe how I balance my training and recovery while at altitude. Every detail counts!"
—Haley Batten, Garmin-sponsored mountain biker
Ready for every run or ride
From casually running and cycling with friends to preparing for their next big race, athletes can count on Garmin products to help them train smarter and go farther. The latest smartwatches – including Forerunner 70, Forerunner 170, Forerunner 570, Forerunner 970, fēnix® 8 Pro and Venu® 4 – are packed with popular health and fitness features to help runners and cyclists of all abilities achieve their goals. Garmin's cycling collection includes Edge GPS cycling computers with bike-specific mapping and advanced training features, as well as Rally™ pedal-based power meters, Varia™ smart lights and rearview radars that warn of approaching cars and Tacx® indoor smart trainers to help cyclists train smarter year-round.
Engineered on the inside for life on the outside, Garmin products have revolutionized life for runners, cyclists, swimmers and athletes of all levels and abilities. Committed to developing technology that helps people stay active and elevate performance, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garmin on social, or follow our blog.
1 Activity tracking accuracy.
About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin, Edge, Forerunner, fēnix and Venu are registered trademarks and Garmin Connect, Index, Rally and Varia are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
MEDIA CONTACTS: Stephanie Kelner and Adrieanna Norse / 913-397-8200 / [email protected]
Garmin (GRMN - Free Report) closed the most recent trading day at $241.96, moving +1.69% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. At the same time, the Dow added 1.73%, and the tech-heavy Nasdaq lost 0.09%.
Heading into today, shares of the maker of personal navigation devices had lost 2.01% over the past month, lagging the Computer and Technology sector's gain of 10.03% and the S&P 500's gain of 4.59%.
The investment community will be closely monitoring the performance of Garmin in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $2.27, reflecting a 4.61% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.93 billion, indicating a 6.41% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $9.53 per share and revenue of $7.98 billion, which would represent changes of +11.33% and +10.12%, respectively, from the prior year.
Any recent changes to analyst estimates for Garmin should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.35% lower. Garmin is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Garmin is currently trading at a Forward P/E ratio of 24.96. This indicates a discount in contrast to its industry's Forward P/E of 30.38.
Investors should also note that GRMN has a PEG ratio of 2.81 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Electronics - Miscellaneous Products industry currently had an average PEG ratio of 1.66 as of yesterday's close.
The Electronics - Miscellaneous Products industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 60, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Listen to the audio version of this article (generated by AI).
Oura is going public at the perfect cultural moment. And that is exactly what makes the IPO dangerous.
The smart-ring maker has confidentially filed its draft IPO paperwork with the Securities and Exchange Commission, according to CNBC. The company says it is on track to pass 5 million paid members this quarter. Revenue has reportedly grown fourfold over the past two fiscal years. Oura was valued at $11 billion last October after a $900 million Series E round, and it has raised more than $1.5 billion in total.
Those are monster numbers. They also explain why this IPO may already have too much good news baked in.
Wall Street has discovered wearable health. Wellness has become dinner-table conversation. People who used to brag about 80-hour weeks now brag about zone 2 cardio, magnesium glycinate, eight hours of sleep, and a morning readiness score.
That shift is real. It may last for decades.
But buying the hottest private company after the market has already found the theme is still a dangerous way to make money.
Just ask Peloton.
The Peloton Warning: Seeing the Future Doesn’t Make the IPO Safe Peloton understood the future early.
Fitness was moving into the home. Hardware could become a social product. A bike could become a media platform. A workout could become a subscription habit.
Peloton was right about the culture. Investors paid pandemic multiples for that story. Then demand normalized, competitors caught up, and the world reopened.
That is the Oura risk in miniature.
Oura may be a great product. It may keep growing. It may even become one of the defining consumer health brands of this decade. The IPO can still be a poor entry point.
At an $11 billion private valuation, Oura is being valued less like a hardware company and more like a platform. CEO Tom Hale told CNBC the company was on track for about $1 billion in 2025 sales and could approach $2 billion in 2026. Even if it hits the high end of that 2026 target, the last private valuation still implies roughly 5.5x those future sales.
That can work if Oura proves it has high-retention software economics. Though the math gets much tougher if the S-1 shows a premium hardware business with a subscription wrapper.
Hardware gets copied. Sensors get cheaper. Wellness fads cool. The winner turns health obsession into durable habits, services, locations, devices, records, and treatment loops.
Oura owns a strong measurement point. The public-market winners could own the rest of the system.
The Health Boom Is Much Bigger Than the Oura Ring Oura’s pitch is simple: a small device watches your body all day and all night, then turns that stream of signals into advice.
That sounds like a ring story. The trail of money is bigger.
People are changing what they spend on. More dollars are going into health, energy, fitness, sleep, appearance, longevity, and self-command. A premium gym membership can signal more than a nicer briefcase. A shoe rotation can matter more than another suit. A lab panel, a running watch, GLP-1 care, a recovery score, or a training plan can become part of how someone sees themselves.
Oura is following the money. It has:
Pushed into AI coaching through Oura Advisor Moved into metabolic health through Veri and a Dexcom partnership Launched Health Panels with Quest Diagnostics, offering about 50 biomarkers for $99 with in-app interpretation. Bought medical-record technology through Galen AI Invested in women’s health, cardiovascular risk, and enterprise wellness. That is the correct map.
The issue is ownership. How much of the economics can Oura keep when the same trend feeds gyms, shoes, watches, phones, labs, treatment platforms, and clinical data companies?
10 Wellness Stocks to Buy Instead of the Oura Ring IPO As it turns out, a lot of those better-positioned stocks are already public.
Life Time: the Cleanest Lifestyle Play Life Time Group (LTH) may be the most culturally relevant stock in this whole basket. Oura tracks the body. Life Time gives the body somewhere to go.
The company operates premium athletic country clubs built around fitness, recovery, pools, classes, childcare, coworking, cafes, spas, and social life.
For a certain kind of buyer, the new status symbol is a body that works, a sleep score that is decent enough to share, a trainer, a sauna, a pickleball court, and a place to spend Saturday morning without feeling like garbage. That is Life Time’s lane.
Sales: $3.1 billion | Quarterly growth: 11.7% | Operating margin: 16.9% | Forward P/E: ~19x Risks: real estate, debt, consumer spending, premium-gym execution The trend fit is unusually clean. This is the higher-upside lifestyle pick. Garmin: the Better Wearable Business Garmin (GRMN) is the cleaner public wearable stock. It wins through trust instead of fashion — runners, cyclists, hikers, divers, pilots, golfers, and endurance athletes buy Garmin because the products work.
Its fitness segment revenue rose 42% year over year in Q1 2026.
Sales: $7.5 billion | Quarterly growth: 14% | Operating margin: 26% | Profit margin: 23% Garmin is mature, profitable, and built for committed users — not wellness tourists. Hims & Hers Owns the Action Layer Hims & Hers (HIMS) is a very different kind of Oura-adjacent stock. Oura measures and nudges. Hims sells action.
The company has built a direct consumer health funnel across sexual health, dermatology, mental health, weight loss, and GLP-1-related care. It also has a natural path into biomarkers, diagnostics, and AI coaching — giving it a broader monetization surface than a wearable brand.
Sales: $2.4 billion | Gross margin: 57% | Price-to-sales: 2.5x | Short interest: ~31% of float The short interest tells you the market sees both sides. Hims has more upside than the mature names — and more ways to get hurt. Quest: the Boring Biomarker Engine Quest Diagnostics (DGX) is dull in a useful way.
Oura’s Health Panels run through Quest — but Quest already does this job at much larger scale. It runs bloodwork and biomarker testing for physicians, hospitals, employers, and direct consumers. Oura is one front door into that lab system. It is not the whole building. Consumer-direct revenue at questhealth.com grew in the high-20% range in Q1, with partnership-driven testing growing even faster.
Sales: $11.3 billion | Quarterly growth: 9.2% | Operating margin: 14.6% | Forward P/E: ~16.7x Bloodwork is harder to hand-wave than a readiness score. DGX is the boring toll road behind the shiny wearable. Dexcom: the Better Oura-Linked Sensor Play Dexcom (DXCM) invested in and partnered with Oura — combining glucose data with sleep, activity, and recovery signals. It is already profitable, already scaled, and already central to the continuous-glucose-monitoring market.
Sales: $4.8 billion | Quarterly growth: 15% | Operating margin: 21.5% | Forward P/E: ~23x Risks: reimbursement, competition, pricing, and the pace at which CGM expands beyond diabetes into mainstream metabolic health. If metabolic tracking becomes a normal consumer habit, Dexcom is one of the cleaner public ways to play it. Google Just Made the Oura Trade More Dangerous Earlier this month, Google announced Fitbit Air — a screenless fitness tracker starting at $99.99, designed for 24/7 health monitoring, paired with Google Health Coach, a Gemini-powered fitness, sleep, and wellness advisor.
Alphabet (GOOGL) is a mature mega-cap with health optionality. Fitbit Air will barely move its revenue by itself. The bigger point: Google has Android, Fitbit, Gemini, cloud infrastructure, and consumer reach. If wearable health becomes an AI coaching market, Google competes at the software layer while Oura fights hardware margin pressure.
Oura may sell a better object. Google may own the decision layer.
Apple: Best Device Footprint, Hardest AI Question Apple (AAPL) belongs in this conversation whether Oura bulls like it or not. The Apple Watch is already on millions of wrists. The Health app already sits on the iPhone. Apple has the hardware, the trust, the privacy pitch, the payments relationship, and the developer ecosystem.
The caveat: Apple’s health-coaching ambitions have lagged its hardware. The AI layer isn’t ready yet. Apple can still win — the win may just arrive later and with less force than investors expect.
AAPL is a core trend participant. It is a slower, safer way to own the theme.
Tempus and Illumina: the Health-Data Brain and Plumbing Tempus AI (TEM) and Illumina (ILMN) are the data stack under the ring-stock story.
Tempus sits closer to oncology, clinical AI, and diagnostics than to consumer wellness.
Sales: $1.4 billion | Quarterly growth: 36% | Gross margin: 62% | Operating margin: negative | Short interest: ~25% Speculative growth — higher upside, higher drawdown risk If AI health-data platforms work, Tempus could matter. If investors tire of unprofitable AI-health stories, it can get punished fast. Illumina is the sequencing infrastructure name — less sexy after years of overhangs, but still near the base of biology-as-data.
Sales: $4.4 billion | Operating margin: 20.6% | Profit margin: 19.4% | Forward P/E: ~25x If longevity, prevention, and cancer screening keep expanding, sequencing remains part of the machinery. Deckers: the Lifestyle Dividend Deckers (DECK), through Hoka, captures the easiest version of the trend to understand. Hoka sits directly in the behavior shift toward walking, running, and low-impact endurance training.
Sales: $5.5 billion | Quarterly growth: 8.7% | Operating margin: 22.8% | Forward P/E: ~13.7x Profitable, real trend exposure; fashion-cycle risk. This is the “touch grass and buy better shoes” part of the health trade.
Two Cautionary Tales: What Not to Buy In the Wellness Boom Peloton (PTON) and Lululemon (LULU) are cautionary tales worth studying — and leaving off the buy list.
Peloton proves that trend accuracy cannot save a stock when the valuation, hardware cycle, and demand assumptions break.
Lululemon proves that wellness identity alone is thin protection. The brand can still be valuable. The stock can still be cheap. The growth story has lost its clean shape, and Mirror already showed how hard it is to bolt connected fitness onto an apparel brand.
They are worth knowing. Neither belongs on the buy list.
The Bottom Line: Let Someone Else Buy the Oura Ring IPO Oura is part of an undeniable boom. Yet that alone only gets investors so far.
This company is going public after the market already understands the story: sleep tracking, recovery, metabolic health, AI coaching, preventive care, and longevity. The product is cool. The brand is strong. The growth is impressive.
The stock may still be a trap if investors pay platform prices before the S-1 proves platform economics.
I want to see the revenue split and hardware gross margin versus subscription gross margin. I want to see churn, paid-member attach rate, cohort retention, customer acquisition cost, replacement cycles, and the economics of labs, CGMs, employer programs, and AI coaching.
Until then, I would let someone else buy in at IPO-hype prices.
The better trade is to buy the companies that can survive after the fad burns off.
Oura may become a great company. It may even become a staple of health wearables someday, the kind of product people put on at night as automatically as they charge their phone.
That still says very little about whether the stock will be a good deal on IPO day. A great product can come public at a bad price. In this market, the better way to play the health boom may be to skip the IPO and buy the companies already holding the pieces that last.
Oura won’t be the last IPO to test your discipline this year.
The window is already closing on what I believe are the two most important pre-IPO trades in a generation. Most investors will find out about them on IPO day — which is precisely when the best opportunity has already passed.
I’ve spent months mapping the ecosystem. I know which stocks I want to own before the headlines arrive.
Here’s what’s on that list — and why the clock is running.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Company announces record date and payment date for June 2026 dividend installment
, /PRNewswire/ -- At Garmin Ltd.'s annual shareholders' meeting held today, approval was received from the shareholders in accordance with Swiss corporate law for a cash dividend in the amount of $4.20 per share, payable in four equal installments. The Board has determined that the June installment of the dividend will be paid as indicated below and currently anticipates the scheduling of the remaining quarterly dividend installments as follows:
Dividend Payment Date
Record Date
Dividend Per Share
June 26, 2026
June 15, 2026
$1.05
September 25, 2026
September 11 2026
$1.05
December 24, 2026
December 11, 2026
$1.05
March 26, 2027
March 12, 2027
$1.05
About Garmin Ltd:
Engineered on the inside for life on the outside, Garmin products have revolutionized the aviation, automotive, fitness, marine and outdoor markets. Dedicated to helping people make the most of the time they spend pursuing their passions, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Garmin Ltd. (NYSE: GRMN) is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. For more information, visit Garmin's virtual Newsroom, email our press team, or follow us on LinkedIn.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors that are described in the Annual Report on Form 10-K for the year ended December 27, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). A copy of Garmin's 2025 Form 10-K can be downloaded from https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Garmin shareholders approve quarterly dividend through March 2027 PR Newswire
SCHAFFHAUSEN, Switzerland, June 5, 2026
Company announces record date and payment date for June 2026 dividend installment
, /PRNewswire/ -- At Garmin Ltd.'s annual shareholders' meeting held today, approval was received from the shareholders in accordance with Swiss corporate law for a cash dividend in the amount of $4.20 per share, payable in four equal installments. The Board has determined that the June installment of the dividend will be paid as indicated below and currently anticipates the scheduling of the remaining quarterly dividend installments as follows:
Dividend Payment Date
Record Date
Dividend Per Share
June 26, 2026
June 15, 2026
$1.05
September 25, 2026
September 11 2026
$1.05
December 24, 2026
December 11, 2026
$1.05
March 26, 2027
March 12, 2027
$1.05
About Garmin Ltd:
Engineered on the inside for life on the outside, Garmin products have revolutionized the aviation, automotive, fitness, marine and outdoor markets. Dedicated to helping people make the most of the time they spend pursuing their passions, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Garmin Ltd. (NYSE: GRMN) is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. For more information, visit Garmin's virtual Newsroom, email our press team, or follow us on LinkedIn.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors that are described in the Annual Report on Form 10-K for the year ended December 27, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). A copy of Garmin's 2025 Form 10-K can be downloaded from https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/garmin-shareholders-approve-quarterly-dividend-through-march-2027-302792837.html
Innovative auto racing radar system provides visual alerts for approaching vehicles to improve awareness and support defense performance
, /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the unrivaled Garmin Catalyst™ R1 racing radar, purpose-built to provide high-performance drivers with more situational awareness1 in their vehicle for a competitive advantage on the racetrack. The radar system features heads-up indicator lights that are positioned within the driver's line of sight in the cockpit, allowing them to keep their eyes on the track and maintain awareness of vehicles approaching from behind.
Innovative auto racing radar system provides visual alerts for approaching vehicles to improve awareness and support defense performance. "We're excited to bring our radar expertise to high-performance driving, furthering our commitment to the motorsports racing community. The Garmin Catalyst R1 is a first-of-its-kind radar system that allows drivers to improve overtaking, defending and on-track decision-making without compromising their focus."
—Susan Lyman, Garmin Vice President of Consumer Sales and Marketing
Designed to race
The Garmin Catalyst R1 radar is unobtrusive, rugged and has an IP67 dust/water rating that can withstand rigorous racetrack conditions including weather, heat and vibration. Along with the indicator lights and rear-facing sensor, the radar system includes all mounting hardware needed to secure on a race vehicle.
Available to purchase on garmin.com starting June 12, 2026, the Garmin Catalyst R1 racing radar has a suggested retail price of $799.99. Visit our website to learn more.
Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garminoutdoor on social, or follow our blog.
1
Adverse weather conditions and wet racetracks may interfere with operation of the device. Always maintain awareness of your surroundings while using this device, especially in these conditions.
About Garmin: Garmin Ltd. (NYSE: GRMN) is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark and Garmin Catalyst is a trademark of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
MEDIA CONTACTS:
Mike Cummings and Connor Hoffman
913-397-8200
[email protected]
The stock market is on a tear. Driven by renewed enthusiasm for artificial intelligence (AI), the S&P 500 index is up 6.3% over the last month, while the tech-heavy Nasdaq Composite is up a whopping 9.4%.
The run, along with a major announcement from the U.S. Commerce Department, has kicked off a rally in quantum computing stocks. As investors look for the "next AI," they're snapping up shares of companies like IonQ, D-Wave, and, of course, Rigetti Computing (RGTI +6.51%).
With the recent launch of its most powerful quantum system to date, many investors believe that Rigetti is one of the most promising quantum pure-plays around. But what about the stock? After jumping more than 50% in a month, is it still a buy? Could shares of Rigetti reach $50?
Today's Change
(
6.51
%) $
1.26
Current Price
$
20.71
Why Rigetti is turning heads in the quantum computing race Rigetti builds superconducting quantum computers, using the same basic approach as Alphabet's Google and IBM. This gives the company's systems a few advantages: speed and scale.
Rigetti just launched its most powerful computer to date, the 108-qubit Cepheus-1-108Q. ,
Beyond the tech itself, the company designs and builds everything in-house, from the quantum chips to the software that runs on them. If its approach delivers, Rigetti would own the entire vertical, giving it a major leg up.
As for financials, revenue nearly tripled year over year last quarter, and the company is sitting on more than $400 million in cash, double what it held a year ago.
And of course, there is the recent news: The U.S. government will provide $100 million to Rigetti as part of a larger $2 billion quantum investment package. That's a pretty big deal.
Image source: Getty Images.
The risks hiding behind Rigetti's explosive stock rally Revenue nearly tripled last quarter, rising from $1.5 million to $4.4 million. At that scale, the growth percentages don't mean much. And the company is still deeply cash-flow negative, burning $20 million in free cash flow (FCF) this quarter.
Of course, there is the valuation issue: Shares currently trade at a price-to-sales (P/S) ratio of nearly 900. The word extreme could be applied here.
Rigetti's technology is promising, no doubt, but it is still just that -- a promise. The company has a runway to keep researching for years, but that's essentially what you're buying here -- research. This is not really a true business at this point.
And as exciting as the government deal is, the $100 million in funding is essentially a grant. The money will be used to fund research and development on an unproven technology in its infancy.
Could Rigetti stock actually reach $50? So, could shares hit $50? Absolutely. In fact, they probably will. But critically, I don't think they'll stay there.
Once the current rally cools and investors start fleeing speculation, a company trading at 900 times sales with $4.4 million in quarterly revenue is going to get crushed.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Rigetti Computing, Inc. (RGTI - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Rigetti Computing currently has an average brokerage recommendation (ABR) of 1.75, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 12 brokerage firms. An ABR of 1.75 approximates between Strong Buy and Buy.
Of the 12 recommendations that derive the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 58.3% and 8.3% of all recommendations.
Brokerage Recommendation Trends for RGTI
Check price target & stock forecast for Rigetti Computing here>>>
The ABR suggests buying Rigetti Computing, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is RGTI Worth Investing In?In terms of earnings estimate revisions for Rigetti Computing, the Zacks Consensus Estimate for the current year has declined 35.5% over the past month to -$0.18.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Rigetti Computing. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Rigetti Computing with a grain of salt.
Key Takeaways Rigetti signed an LOI for up to $100M in U.S. funding to advance superconducting quantum computing.Proposed funding could support R&D, ease balance-sheet pressure and speed commercialization efforts.The agreement would give the U.S. Commerce Department an equity stake tied to funding awarded. Rigetti Computing (RGTI - Free Report) recently announced that it has signed a letter of intent (LOI) with the U.S. Department of Commerce for an award of up to $100 million over three years to accelerate research and development efforts in superconducting quantum computing. The proposed funding, which falls under the CHIPS Act's Research and Development Office program, is intended to support projects aimed at overcoming key technical challenges associated with scaling quantum computers.
The agreement underscores the U.S. government's commitment to strengthening domestic leadership in next-generation technologies and positions Rigetti among a select group of companies expected to play a critical role in advancing the country's quantum computing capabilities. Under the terms of the LOI, the Department of Commerce would receive an equity stake in Rigetti tied to the amount of funding ultimately awarded.
The development represents a meaningful strategic and financial catalyst for Rigetti as it seeks to accelerate the commercialization of its quantum computing platform. The potential funding could help the company pursue ambitious R&D initiatives without placing additional pressure on its balance sheet, while speeding efforts to address scalability bottlenecks that remain a key hurdle for the broader quantum industry.
Management believes the investment will bring Rigetti closer to utility-scale quantum computing, a milestone that could unlock opportunities across national security, advanced materials research, drug discovery, financial modeling and energy applications. Beyond the capital infusion, the government's willingness to partner with Rigetti serves as a strong endorsement of the company's technology and may strengthen its competitive position as quantum computing investment and adoption continue to expand.
Peers UpdatesIonQ (IONQ - Free Report) recently opened a new 22,000-square-foot quantum computing R&D laboratory and semiconductor chip testing facility in Boulder, CO, to support the development of future generations of its trapped-ion quantum computing systems. The facility will enable the company to design, test and refine advanced semiconductor ion-trap chips, with plans to install its first quantum computer later this year. By expanding its presence in Colorado's growing quantum technology ecosystem and leveraging the region's deep-tech talent pool, IONQ aims to accelerate innovation, scale production capabilities and advance its roadmap toward fault-tolerant quantum computing.
D-Wave Quantum (QBTS - Free Report) also recently announced that it has signed an LOI with the U.S. Department of Commerce for $100 million in proposed funding under the CHIPS and Science Act to accelerate the development and scaling of its annealing and gate-model quantum computing technologies. The funding, which would be accompanied by a $100 million equity stake for the U.S. government, is expected to support quantum system development at D-Wave’s upcoming Boca Raton, FL, facility and its existing R&D centers. The initiative could help accelerate the delivery of advanced quantum systems, including a 100,000-qubit annealing computer and a 10,000-qubit gate-model system, while strengthening the company’s position in the growing quantum computing market and supporting broader U.S. technology leadership objectives.
Rigetti Computing’s Price Performance, Valuation and EstimatesShares of RGTI have gained 15.7% in the year-to-date period against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Rigetti trades at a price-to-book ratio of 14.59, above the industry average. RGTI carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Rigetti’s 2026 earnings implies a significant 70.3% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Rigetti ended Q1 FY26 with $569 million in cash, zero debt, and revenue growth of 198.9% year-over-year. Approximately $2.7-$3.0 million of the Novera QPU order appears positioned for Q2-FY26 revenue recognition. A potential $100 million CHIPS Act investment strengthens funding capacity and supports long-term quantum development efforts.
Rigetti Computing (RGTI +6.51%) stock went on a massive run in May, surging over 46%.
Shares got a boost from a marketwide rally that saw the Nasdaq Composite gain more than 8%, but better-than-expected Q1 earnings and a major announcement from the federal government both sent the stock higher.
Today's Change
(
6.51
%) $
1.26
Current Price
$
20.71
Federal quantum funding gives Rigetti a major boost On May 21, the U.S. Department of Commerce signed letters of intent to award $2 billion in federal grants to nine quantum computing companies under the CHIPS and Science Act. Aimed at accelerating the development of "utility-scale, fault-tolerant quantum computing," the program was seen as a major endorsement from the federal government.
Source: Getty Images
Rigetti will receive up to $100 million over three years, per a letter of intent. That's a pretty big sum for a company that generated just $4.4 million in revenue last quarter, and it helps provide a financial runway.
Shares jumped nearly 57% on the day of the announcement and the day following.
The CHIPS Act announcement was a big moment for the whole quantum industry. Rigetti was far from the only pure play stock to see a huge spike on the news.
Q1 earnings beat expectations as revenue nearly triples Earlier in the month, Rigetti released its Q1 2026 earnings. Revenue came in at $4.4 million, a nearly 200% year-over-year increase and well above analyst targets. The growth was driven by deliveries of the company's Novera quantum processing units, as well as netting some government contracts.
The company is still burning cash, however, with a free cash flow (FCF) of -$20.6M.
MetricQ1 2026Q1 2025Revenue$4.4M$1.5MEBITDA($23.3)($19.8)Cash418.3M209.1M Cepheus finally launches The company also hit an important technical milestone. Rigetti's 108-qubit Cepheus system was finally released. The company says it achieved "two-qubit gate fidelity" of roughly 99.1%, with targets of 99.5% fidelity and 150-plus qubits by year-end.
The Cepheus system had been delayed, so its successful launch was a critical win.
IBM's $10 billion quantum commitment helps boost shares Right at the end of the month, IBM added fuel to the rally by announcing plans to invest more than $10 billion in quantum computing. Over the next five years, the company plans to invest that money in R&D, manufacturing, and "ecosystem partnerships".
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends International Business Machines. The Motley Fool has a disclosure policy.
A $10,000 position in the Defiance Quantum ETF (NYSEARCA:QTUM) on the last trading day of 2025 was worth about $15,420 by the close on June 2, 2026, a 54.2% year-to-date move from a starting price of $109.44 to $168.76. Over the same stretch the S&P 500, as proxied by SPY, returned 11%, and the Nasdaq-100 via QQQ, the closest thing to a clean Magnificent 7 wrapper, returned 21%. A theme ETF beating the broad market by a factor of nearly five in five months is the kind of number that sends people to Google, and that is what you are doing here.
QTUM is a straightforward thematic vehicle. It tracks the BlueStar Quantum Computing and Machine Learning Index, holds roughly 70 to 80 names on an equal-weighted basis, charges a 0.40% expense ratio, and has been trading since September 2018. The $23.21 launch-window price sits well in the rear-view mirror, with the fund up 627% since inception and 99% in the trailing year alone. The 2026 surge is therefore the second leg of a move that was already running.
What actually did the work Equal weighting matters here, because it means the run is not the product of one or two names dragging an index higher in a Mag 7-style top-heavy way. The run is the product of the bench, with the equal-weighted structure preventing any one or two names from dragging the index higher Mag 7 style. That said, the pure-play quantum names inside QTUM have done staggering fundamental work this year, and they are the easiest place to start.
IonQ (NYSE:IONQ | IONQ Price Prediction) reported Q1 2026 revenue of $64.67 million, growth of 755% year over year, and the company raised full-year guidance to $260 million to $270 million while telling the Street to expect adjusted EBITDA losses of ($330) million to ($310) million. Remaining performance obligations stood at $470 million, up 554% year over year. CEO Niccolo de Masi described it as "our fourth consecutive quarter of record-breaking results and the biggest quarter in our company’s history". The stock is up 59% YTD and 55% in the last month alone.
Rigetti Computing (NASDAQ:RGTI) is the smaller, noisier sibling. Q1 revenue came in at $4.4 million against $1.47 million a year earlier, nearly a triple, and the company is sitting on $569 million in cash and investments with no debt. The 108-qubit Cepheus-1-108Q is now generally available on Rigetti QCS, Amazon Braket, Microsoft Azure Quantum, and qBraid, with median two-qubit gate fidelity of 99.8% and prototype results as high as 99.9%. CEO Subodh Kulkarni called Cepheus-1-108Q "one of the most powerful generally available gate-based quantum computers in the world". The stock is up 21% YTD but more than doubled over the trailing year at 119%.
The fundamentals are real, with the usual caveat that real means "triple-digit growth off a tiny base." IonQ is still posting an adjusted EBITDA loss of ($97) million per quarter and burned $151 million in operating cash. Rigetti’s GAAP net income of $33 million is almost entirely a $54 million non-cash swing in derivative warrant liabilities, not a business turning a profit. These are venture-style stories trading inside a public-market wrapper. The mechanism that lifted QTUM is partly that the wrapper itself, an equal-weighted basket, lets you ride the theme without picking which trapped-ion or superconducting bet survives.
The bench, the chips, and the AI overlap The other engine is the "and Machine Learning" half of the index name. QTUM owns a long tail of semiconductor, networking, and cloud-infrastructure names that have benefited from the same AI capex wave powering the Magnificent 7. Goldman Sachs noted in its 2026 outlook that the AI capex boom has become the dominant business and investment engine in the US economy, with growth based on "long-term transformative investments potentially masking the true nature of the underlying real economy." Vanguard framed 2026 as the year AI gets "embedded in workflows" with a possible compute-paradigm shift if the "hoped-for quantum leap in AI capability remains elusive." That is the macro tailwind sitting under the basket.
So you have two stacked tailwinds inside one fund. Pure-play quantum names compounding from microscopic revenue bases at triple-digit growth rates, and AI-adjacent semis and cloud platforms riding the same capex story that has lifted QQQ 21% YTD. Equal weighting then amplifies the quantum half. In a market-cap-weighted theme fund, a name like Rigetti at an $8.93 billion market cap would be a rounding error next to NVIDIA. In QTUM, it gets the same slot as the largest holdings on every rebalance. That is the structural reason the ETF outran the Mag 7 in 2026 even though the Mag 7 itself had a fine year.
Real progress or sentiment Both, and the proportions matter. The revenue numbers at IonQ are verifiable filings. About 60% of revenue is commercial and 35% international, and the company shipped its first 256-qubit system to the University of Cambridge along with DARPA, Space Development Agency, and Missile Defense Agency contracts. Government and defense buyers writing real checks for real hardware is a different signal than press-release qubit counts.
What is harder to defend is valuation. IonQ carries a market cap of roughly $26.65 billion against full-year revenue guidance topping out at $270 million, which works out to a price-to-sales ratio in the high double digits even on the optimistic line. Rigetti is at $8.93 billion on $4.4 million of quarterly revenue, which is a sentence that does not require commentary. One AI-focused podcast guest captured the mood when discussing the sector last cycle, noting that two of the quantum names "have like 7 billion in equity value between them and they have like less than 10 million in trailing revenue" and calling it a "total bubble." The valuations have only stretched since.
Polymarket, for what it is worth, has a market on whether the US federal government will take a stake in IonQ resolving by year-end, with Yes priced at 44% and No at 56%. That is the kind of question that exists in a sentiment regime, not in a sober one.
What to watch from here The forward case for QTUM has three legs, and you can monitor each of them without a Bloomberg terminal.
First, watch IonQ’s revenue cadence against the Q2 guide of $65 million to $68 million and the full-year $260 million to $270 million bar. The basket re-rated this year because IonQ delivered a 30% beat on Q1 guidance midpoint. A clean in-line report would still be acceptable. A miss would tell you the growth curve is bending, and at these multiples that matters more than direction.
Second, watch the AI capex line. The leading indicators are the hyperscaler capex commitments each quarter and the bond-issuance pace from AI-oriented names, which Goldman flagged as having become more active in the 2025 corporate bond market. QTUM’s quantum-adjacent half rides that wave. If capex guidance starts coming down, the chip and cloud bench inside the fund stops contributing and the burden falls entirely on a small pile of pre-revenue quantum names that cannot carry it alone.
Third, watch fidelity benchmarks and customer announcements rather than qubit-count headlines. 99.8% median two-qubit gate fidelity on a generally available 108-qubit system is the kind of number that determines whether quantum advances from a science project to something a pharmaceutical company will pay seven figures to access. That is the real fundamental dial.
The honest read is that QTUM’s 2026 is a regime trade riding two tailwinds at once, and the trade worked because the equal-weighted structure let a handful of small, fast-growing pure-plays do disproportionate work alongside an AI-adjacent bench. The mechanism is intact today. It is also expensive today. A QTUM bought at $168.76 is a different security than one bought at $109.44 on January 2, even with the same ticker and the same prospectus. The number to remember is the gap between QTUM’s 54% and SPY’s 11%. Gaps that wide rarely repeat from the new starting line, and the question for the next five months is whether the IonQ guide for Q2 lands above $68 million.
I've got bad news and good news for Rigetti Computing (RGTI +6.51%) investors today.
Bad news first: Rigetti stock is plunging 11.6% through 11:30 a.m. ET Friday. And the good news?
Image source: Getty Images.
No bad news for Rigetti Computing The good news is that there's no specific bad news behind the sell-off -- no earnings reports that missed targets, no analyst downgrades, not even so much as a lowered price target on Wall Street. Instead, Rigetti stock seems to be going down simply because everything tech is selling off today: Bitcoin (BTC +2.62%) is off nearly 5% so far this morning, Nvidia (NVDA +2.30%) shares are off a similar amount, while memory company Micron (MU +11.48%) is down even more.
Basically, what we're looking at here is just a "risk-off" day for the market.
What sparked it? The most likely catalyst seems to be worries over Broadcom's (AVGO +3.54%) earnings report Wednesday night. Broadcom spooked investors when it warned that sales of its artificial intelligence chips will "only" triple in Q3, and not grow even faster, as analysts had hoped.
And now everyone is panicking about everything tech, quantum computing stocks included.
Today's Change
(
6.51
%) $
1.26
Current Price
$
20.71
So, is it safe to buy Rigetti stock? Just knowing why Rigetti stock is selling off doesn't necessarily mean it's safe to buy it, however. As a technology and as an industry, quantum computing is still in its infancy and probably years away from being a profitable endeavor.
In the case of Rigetti, analysts polled by S&P Global Market Intelligence don't expect profits to arrive as far out as analysts are willing to make forecasts (which is 2030), with the company burning through hundreds of millions of dollars in cash along the way. Before buying this dip, make sure to check your risk tolerance first.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Broadcom, Micron Technology, and Nvidia. The Motley Fool has a disclosure policy.
Rigetti Computing (NASDAQ:RGTI) is back in every quantum chat room after running 53.6% in a month on hopes that its 108-qubit system finally turns research into revenue. But here’s what you should actually be watching.
The Rigetti story sounds great until you read the income statement. Full-year 2025 revenue declined to $7.09 million from $10.79 million in 2024, a 34.31% drop. Q1 2026 looked better on the surface at $4.4 million, but the headline $33.1 million GAAP net income came from a $53.7 million favorable swing in derivative warrant liabilities, an accounting artifact, while the actual operation lost $26 million and burned $16.2 million in operating cash. Management offers no formal revenue guidance, and Rigetti itself flags fault-tolerant quantum computing as a longer-term objective with an uncertain timeline.
Now stack that against the valuation. Alpha Vantage pegs the trailing price-to-sales ratio at 867 on $10 million in trailing revenue. The CFO and CTO have been disposing of stock into the rally, with the CTO unloading nearly 19,000 shares on May 22, 2026. Retail is already wobbling: r/stocks discussions on May 22, 2026 ran “very bearish” with posts like “Quantum stocks are sham / don’t buy the pop today.” When the only thing growing reliably is the share count, that signals a hype cycle.
IonQ (NYSE:IONQ | IONQ Price Prediction) is doing what Rigetti keeps promising. Three reasons it deserves your attention instead.
1. A real, contracted backlog IonQ closed Q1 2026 with remaining performance obligations of $470 million, up 554% year over year. That is contracted, visible future revenue, the kind of number retirement investors should care about. Rigetti’s order book is still measured in one-off chip sales.
2. Enterprise validation across clouds and customers IonQ is the only pure-play quantum provider natively integrated across all three major public clouds (Amazon AWS, Microsoft Azure, and Google Cloud). Q1 brought the first 256-qubit system sale to the University of Cambridge, a $39 million Space Development Agency HALO contract, selection for the Missile Defense Agency SHIELD IDIQ, and selling into more than 30 countries. Revenue mix is roughly 60% commercial and 35% international. That is enterprise utility at commercial scale.
3. Scale, growth, and a cash cushion to fund it Q1 revenue hit $64.7 million, up 755% year over year and 30% above the midpoint of guidance. Management raised full-year guidance to $260 million to $270 million, with organic growth over 100%. CEO Niccolo de Masi told investors IonQ is “raising our revenue expectations for the full year to $270 million at the high end, based upon the strong and growing demand for our leading quantum computers.” The company sits on $493.5 million in cash against shareholders’ equity of $4.99 billion, with a pending SkyWater Technology acquisition aimed at vertically integrating chip fabrication.
Both names burn cash. Both trade at speculative multiples. The difference is that IonQ already shipped a fourth consecutive record quarter, has guidance you can model, and a backlog Wall Street can underwrite. Rigetti has a balance sheet and a story.
What to watch next: IonQ’s ability to convert its $470 million backlog into recognized revenue, and whether Rigetti can produce organic top-line growth to justify its valuation.
Rigetti Computing, Inc. (RGTI - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this company have returned +9.2% over the past month versus the Zacks S&P 500 composite's +1.9% change. The Zacks Internet - Software industry, to which Rigetti Computing belongs, has gained 1.7% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Rigetti Computing is expected to post a loss of $0.03 per share, indicating a change of +40% from the year-ago quarter. The Zacks Consensus Estimate has changed -37.5% over the last 30 days.
The consensus earnings estimate of -$0.18 for the current fiscal year indicates a year-over-year change of +71.9%. This estimate has changed -38.7% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.18 indicates a change of +0.9% from what Rigetti Computing is expected to report a year ago. Over the past month, the estimate has changed +5.9%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Rigetti Computing is rated Zacks Rank #4 (Sell).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Rigetti Computing, the consensus sales estimate for the current quarter of $4.91 million indicates a year-over-year change of +173%. For the current and next fiscal years, $25.32 million and $52.04 million estimates indicate +257.3% and +105.5% changes, respectively.
Last Reported Results and Surprise HistoryRigetti Computing reported revenues of $4.4 million in the last reported quarter, representing a year-over-year change of +199.3%. EPS of -$0.04 for the same period compares with -$0.08 a year ago.
Compared to the Zacks Consensus Estimate of $3.24 million, the reported revenues represent a surprise of +35.59%. The EPS surprise was +20%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates just once over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Rigetti Computing is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Rigetti Computing. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
Key Takeaways RGTI made its 108-qubit Cepheus-1-108Q system broadly available across major quantum platforms.RGTI's Q1 revenue nearly tripled to $4.4 million, driven by Novera QPU deliveries and contracts.Rigetti targets quantum advantage with a ~1,000-qubit system, 99.9% gate fidelity and error mitigation. Rigetti Computing (RGTI - Free Report) is strengthening its position in the quantum computing race through a combination of technological advancements and expanding customer adoption. During the first quarter of 2026, the company made its 108-qubit Cepheus-1-108Q system generally available through Rigetti Quantum Cloud Services, Amazon Braket, Microsoft Azure Quantum and qBraid. Management believes the platform is among the world’s most powerful gate-based quantum computers and the largest modular quantum computing system currently on the market.
Built using 12 interconnected 9-qubit chiplets, the system validates Rigetti’s chiplet-based scaling architecture, a key element of its long-term roadmap toward larger and more capable quantum systems. The company also highlighted continued progress in improving gate fidelity and performance, with management targeting approximately 99.5% median two-qubit gate fidelity later in 2026 while maintaining its speed advantages.
Beyond technology milestones, Rigetti continues to gain customer traction across both cloud and on-premises deployments. First-quarter revenues nearly tripled year over year to $4.4 million, primarily driven by deliveries of Novera quantum processing units (QPUs) and related contracts. The company continues to expand its installed base through sales to universities, research institutions and national laboratories. It is also reporting growing interest from commercial customers in industries such as materials science, logistics and financial services.
Importantly, management reiterated its belief that Rigetti can achieve quantum advantage within roughly three years, targeting a system with around 1,000 qubits, 99.9% two-qubit gate fidelity and integrated error mitigation capabilities. Backed by approximately $569 million in cash and no debt, Rigetti is well positioned to continue investing aggressively in scaling its technology platform and capitalizing on emerging opportunities in the rapidly evolving quantum computing market.
Peers UpdatesIonQ (IONQ - Free Report) recently opened a new 22,000-square-foot quantum computing R&D laboratory and semiconductor chip testing facility in Boulder, CO, to support the development of future generations of its trapped-ion quantum computing systems. The facility will enable the company to design, test and refine advanced semiconductor ion-trap chips, with plans to install its first quantum computer later this year. By expanding its presence in Colorado's growing quantum technology ecosystem and leveraging the region's deep-tech talent pool, IONQ aims to accelerate innovation, scale production capabilities and advance its roadmap toward fault-tolerant quantum computing.
D-Wave Quantum (QBTS - Free Report) recently announced that it has entered into a non-binding Letter of Intent with the U.S. Department of Commerce for proposed funding of up to $100 million under the CHIPS and Science Act. The initiative aims to support the advancement and large-scale deployment of the company’s annealing and gate-model quantum computing technologies. As part of the proposed arrangement, the U.S. government would receive a $100 million equity stake in D-Wave.
The funding is expected to help expand quantum system development at D-Wave’s planned facility in Boca Raton, FL, as well as its existing research and development operations. The investment could accelerate the commercialization of next-generation quantum platforms, including a 100,000-qubit annealing system and a 10,000-qubit gate-model computer. It could also enhance D-Wave’s competitive standing in the rapidly evolving quantum computing market and support U.S. leadership in critical advanced technologies.
Rigetti Computing’s Price Performance, Valuation and EstimatesShares of RGTI have lost 1.8% in the year-to-date period compared with the industry’s decline of 11%.
Image Source: Zacks Investment Research
From a valuation standpoint, Rigetti trades at a price-to-book ratio of 12.39, above the industry average. RGTI carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Rigetti’s 2026 earnings implies a significant 70.3% improvement from the year-ago period.
The company currently has a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It has been about a month since the last earnings report for Rigetti Computing, Inc. (RGTI - Free Report) . Shares have added about 3.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Rigetti Computing due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
RGTI Q1 Earnings & Revenues Beat Estimates, Gross Margin UpRigetti reported first-quarter 2026 adjusted loss per share of 4 cents, narrower than the loss per share of 8 cents in the prior-year quarter. The metric also surpassed the Zacks Consensus Estimate of earnings by 20%.
GAAP loss per share in the reported quarter was 6 cents against the earnings per share of 13 cents in the prior-year quarter.
Rigetti’s Revenue DetailsThe company reported total revenues of $4.4 million, up 198.9% year over year. The top line surpassed the Zacks Consensus Estimate by 35.6%.
Rigetti’s first-quarter 2026 revenues were driven primarily by higher sales of its on-premises Novera quantum systems and broader customer adoption across academic, government and research institutions. The commercial rollout of its 108-qubit Cepheus-1-108Q system across major cloud platforms also supported top-line growth.
RGTI’s Margin TrendIn the quarter under review, RGTI’s gross profit improved 211.8% year over year to $1.4 million. The gross margin expanded 130 basis points to 31.3%.
Selling, general and administrative expenses increased 11.4% year over year to $7.4 million. Research and development expenses increased 29.1% year over year to $19.9 million. Total operating expenses of $27.3 million increased 23.8% year over year.
Operating loss for the quarter under review totaled $25.9 million compared with $21.6 million in the prior-year quarter.
RGTI’s Financial PositionRGTI exited the first quarter of 2026 with cash, cash equivalents and short-term available-for-sale investments of $418.2 million compared with $443.5 million at the end of the fourth quarter of 2025.
The company ended the quarter with no debts on its balance sheet.
Net cash used in operating activities at the end of the first quarter was $16.2 million compared with $13.7 million a year ago.
How Have Estimates Been Moving Since Then?Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted -37.5% due to these changes.
VGM ScoresCurrently, Rigetti Computing has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. However, the stock was allocated a score of F on the value side, putting it in the lowest quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook Rigetti Computing has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerRigetti Computing belongs to the Zacks Internet - Software industry. Another stock from the same industry, Nice (NICE - Free Report) , has gained 2.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Nice reported revenues of $768.62 million in the last reported quarter, representing a year-over-year change of +9.8%. EPS of $2.64 for the same period compares with $2.87 a year ago.
Nice is expected to post earnings of $2.63 per share for the current quarter, representing a year-over-year change of -12.6%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.7%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Nice. Also, the stock has a VGM Score of C.
Rigetti Computing (NASDAQ:RGTI) stock is 1.4% higher to trade at $19.97 today. The quantum computing concern is down 9.7% in 2026 and 21% in June alone, as high beta growth stocks have suffered from tech sector profit taking. The upside though, if past is precedent, is that RGTI has pulled back to a historically bullish trendline.
According to Schaeffer's Senior Quantitative Analyst Rocky White, Rigetti stock is trading within 0.75 times of the 50-day moving average's 20-day average true range (ATR), after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above that trendline. This setup has appeared five times during the last decade. One month later, the stock was higher 60% of the time after these signals, averaging a 22.7% gain.
A move of similar magnitude would have RGTI filling its June drawdown, and testing the downtrend line from those October highs above $58, seen below. It's also worth noting Rigetti's 14-Day Relative Strength Index (RSI) is below 50, an area that preceded a frenetic rally in late May.
A short squeeze could help as well. Short interest is down 2% in the most recent reporting periods, yet the 49.21 million shares sold short account for 15% of the shares' total available float.
QBTS stock is moving. See the chart and price action here. The deal, part of a broader $2 billion quantum computing initiative covering nine companies, drew an explicit endorsement from Secretary of Commerce Howard Lutnick, who called the investments a bid to lead “the world into a new era of American innovation.”
The government’s minority, non-controlling stake structure mirrors deals the Trump administration has struck across rare earths, semiconductors and energy — a widening industrial policy playbook now extended to quantum.
The 2032 RoadmapThe federal validation sets the stage for what D-Wave unveiled Monday: a new gate-model roadmap targeting 100 logical qubits capable of executing more than one million operations by 2032 — enough to support early quantum chemistry and quantum AI applications.
The roadmap is built on D-Wave’s superconducting dual-rail qubit architecture, which detects approximately 90% of errors at the single-qubit level as they occur, dramatically reducing the physical qubit overhead required for error correction.
The company has already demonstrated 99.9% two-qubit fidelities with error detection. Key milestones run from a 17-physical-qubit system in 2026 with 2x logical error reduction, through a 181-qubit system in 2028 targeting a 2,000-fold error reduction, to the full fault-tolerant system by 2032.
D-Wave is also targeting a Lambda value of 10 — five times the industry norm — meaning each increment of error correction reduces errors by a factor of 10, not 2.
“Our superconducting dual-rail architecture is a fundamentally different approach to fault-tolerant quantum computing that we expect will position D-Wave not only to compete, but also to redefine how quickly the technology becomes commercial," CEO Dr. Alan Baratz said.
QBTS Stock Price Activity: D-Wave Quantum stock was up 1.96% at $30.73 at the time of publication on Monday, according to Benzinga Pro.
Over the past month, QBTS has gained about 41.2% versus a 4.9% rise in the S&P 500 and is up roughly 17% year-to-date compared to the index’s 10.2% gain.
Photo courtesy of D-Wave Quantum, Inc.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Key Takeaways D-Wave Quantum is among nine firms in DoC letters of intent tied to $2.013B in proposed incentives.QBTS jumped 17.1% in 10 days as investors cheered funding for U.S. quantum expansion.Honeywell's Quantinuum may receive up to $100M to advance trapped-ion quantum computing. Over the past 10 days, the most prominent quantum-computing ETFs, Defiance Quantum ETF (QTUM - Free Report) and WisdomTree Quantum Computing Fund (WQTM - Free Report) , have gained around 7-8%. The rally followed the U.S. Department of Commerce's (DoC) announcement of letters of intent with nine quantum-related companies for approximately $2.01 billion in proposed CHIPS and Science Act incentives.
Image Source: Zacks Investment Research
This proposed funding package represents one of the most significant federal investments in quantum computing to date, reflecting Washington's growing efforts to maintain U.S. leadership in this space. The government currently views this as a strategically important initiative for national security, technological resilience and future industrial competitiveness.
Image Source: Zacks Investment Research
Following this, investor enthusiasm for pure-play quantum stocks surged as market participants reassessed the sector's growth prospects and funding outlook. The proposed federal support has boosted confidence in the industry's long-term potential, driving sharp gains across several quantum names, with D-Wave Quantum (QBTS - Free Report) and Honeywell’s (HON - Free Report) Quantinuum emerging as key beneficiaries of the initiative.
Government Support Accelerates Quantum CommercializationQuantum computing has steadily moved up the U.S. strategic agenda since the passage of the National Quantum Initiative Act in 2018, which established a coordinated federal framework for advancing quantum research and development. The latest funding push builds on those efforts and signals a growing emphasis on accelerating commercialization and domestic manufacturing capabilities.
Reflecting the sector's growing momentum, IBM (IBM - Free Report) subsequently announced plans on May 28 to invest more than $10 billion in quantum computing through 2029. Notably, IBM is also slated to receive up to $1 billion under the proposed quantum funding program for its quantum foundry project.
2 Pureplays in Focus Stock Comparison Since Doc’s Announcement: QBTS, HON
Image Source: Zacks Investment Research
D-Wave: It is one of the nine names in the letters of intent and appears well-positioned to benefit from the DoC initiative. According to the company, the investment would support the expansion of its quantum computing technologies and help accelerate the development of U.S.-based quantum infrastructure. Given D-Wave's relatively modest operating scale, the proposed funding could meaningfully strengthen its balance sheet, support R&D efforts and enhance its ability to commercialize both annealing and gate-model quantum computing systems.
Following the announcement, shares of QBTS have risen 17.1% over the past 10 days. This Zacks Rank #3 (Hold) stock is expected to report earnings growth of 73.9% in 2026.
Sales and EPS Growth Rates (Y/Y %)
Image Source: Zacks Investment Research
Quantinuum (Honeywell): Quantinuum, majority-owned by Honeywell, is also expected to receive up to $100 million under the proposed program. The company said the funding would support the development of its trapped-ion quantum-computing platform and strengthen domestic quantum capabilities. As one of the industry's most advanced quantum-computing companies, Quantinuum is already generating commercial revenues and expanding enterprise adoption. The additional federal backing could help accelerate product development, scale manufacturing capabilities and further solidify its leadership position in the emerging quantum-computing market.
Honeywell has gained 6.3% during this period. This Zacks Rank #3 stock is expected to report earnings growth of 7.7% in 2026. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sales and EPS Growth Rates (Y/Y %)
Image Source: Zacks Investment Research
May 2026 was a big month for D-Wave Quantum Inc. NYSE: QBTS in terms of major funding support.
D-Wave Quantum Today
$23.84 +0.59 (+2.55%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$12.75▼
$46.75Price Target$36.40
Just days after the announcement of a $2 billion funding injection for the quantum computing industry from the U.S. Department of Commerce, including plans for $100 million to go toward D-Wave's continued development of its two-pronged technological approach, the company revealed another bit of support from the government.
D-Wave announced second-year funding for the Improved Materials for Superconducting Qubits with Scalable Fabrication (SQFab) project of NORDTECH.
Get D-Wave Quantum alerts:
The exact funding amount was not specified, but the company's program is one of four sharing collective support of more than $25 million in its efforts toward advancing superconducting qubit fabrication and system scaling.
Government Awards Stack Up as D-Wave Redoubles Technological EffortsBoth the Commerce Department award and NORDTECH's support are dedicated to D-Wave's continued technological advances. In both cases, the projects have fairly broad applications: the $100-million award aims generally for continued development of D-Wave's gate-model and annealing technologies, as the company continues to distinguish itself from peers for its dual approach.
The NORDTECH award is part of an effort to speed up domestic microelectronics prototyping while boosting domestic dominance in quantum computing tech. While NORDTECH is part of an initiative executed by the Naval Surface Warfare Center Crane Division, the project in question has implications well beyond national security. Indeed, if D-Wave is able to help to advance progress on packaging and testing for gate-model quantum systems through this project, it will undoubtedly have major commercial benefits as well.
Award Speaks to D-Wave's Savvy Acquisition HistoryThough D-Wave is technically the recipient of NORDTECH's award, in actuality, the project in question involves D-Wave subsidiary Quantum Circuits, a company that D-Wave acquired at the beginning of 2026. Investors may see the news of this latest bit of funding support as further evidence of D-Wave's foresight in targeting Quantum Circuits as an acquisition in recent quarters.
Prior to the Quantum Circuits purchase, D-Wave distinguished itself from rivals in the quantum space by focusing on annealing tech primarily. While this set D-Wave apart, it led some analysts and investors to grow concerned about potential limitations of that technology relative to the more prominent gate-model approach commonly favored by rivals like IonQ Inc. NYSE: IONQ. In purchasing Quantum Circuits, D-Wave not only boosted its technical expertise, but it also moved beyond a singular approach to become a dual-focus company. NORDTECH's award helps confirm that Quantum Circuits' efforts on the gate-model side remain a worthwhile path for D-Wave to explore.
Adding to D-Wave's Cash PileD-Wave is known in the quantum space for its sizable cash holdings—the company reported more than $588 million in cash and equivalents as of the end of Q1 2026, and that's after completing its purchase of Quantum Circuits earlier in the same quarter. A portion of the $25 million award from NORDTECH is relatively modest compared to that cash pile, but it nonetheless helps the company to continue to build its reserves.
The question now for investors is what D-Wave might do with that money, and when it might choose to deploy it. The firm is well-positioned to institute a share buyback plan if it wishes (and this might be welcome news for investors, given concerns about dilution). It could also initiate additional acquisitions, although with its twin technological approach in operation, it's not immediately clear what type of firm D-Wave might target in that case.
Ultimately, adding to D-Wave's cash simply means that the company has more flexibility, which is always a positive. This is especially crucial for a firm that has continued to face impediments toward achieving profitability.
Trade-Offs From the Award Are FewIt is unclear from the award if D-Wave will give up any equity as part of the award from NORDTECH, although it will issue common stock to the government as part of the Commerce Dept award. This means that the process will be dilutive for investors and may lead to additional influence on the company from the federal government.
Additionally, awards like those provided by NORDTECH are often dependent upon the achievement of certain technical milestones. This means that D-Wave may be subject to review if those goals are not reached—and it may also direct D-Wave's R&D efforts away from other potential pathways. Still, the goal of packaging and scaling for superconducting qubits is fundamental to so much of what the quantum computing industry is aiming to achieve that this seems unlikely to interfere with other goals the company may have.
Should You Invest $1,000 in D-Wave Quantum Right Now?Before you consider D-Wave Quantum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and D-Wave Quantum wasn't on the list.
While D-Wave Quantum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
The Department of Commerce recently announced letters of intent to invest $2 billion across nine quantum computing companies under the CHIPS and Science Act. In exchange, the government will receive a minority equity stake in each business.
With the U.S. government becoming a shareholder in the quantum industry, smart investors should start paying serious attention to how this technology could become the next frontier in artificial intelligence (AI).
Image source: Getty Images.
Why is the government investing in quantum computing stocks? The Commerce Department's rationale behind backing these quantum computing companies was straightforward: These investments will be used to build a domestic manufacturing base for quantum chips and accelerate the research and development (R&D) needed to produce practical quantum computers at scale.
Two recipients in particular are being funded to lead the manufacturing infrastructure. International Business Machines (IBM +0.91%) will receive $1 billion and establish a new quantum foundry subsidiary called Anderon. Meanwhile, GlobalFoundries (GFS +7.91%) is raising $375 million to build a complementary foundry capable of serving broader quantum architectures, including superconducting, trapped-ion, and photonics.
The remaining companies -- Atom Computing, Diraq, D-Wave Quantum (QBTS +2.58%), Infleqtion, PsiQuantum, Quantinuum, and Rigetti Computing (RGTI +6.51%) -- each received up to $100 million in funding to help address specific engineering variables and modalities.
Today's Change
(
6.51
%) $
1.26
Current Price
$
20.71
Among the government's quantum investments, which ones can retail investors buy? Both IBM and GlobalFoundries are publicly traded. However, their primary stories revolve around enterprise technology and semiconductor manufacturing. In reality, quantum computing is a small, niche piece of each company's AI roadmap today.
IBM's exposure to quantum computing is being outsourced to Anderon, a separate subsidiary. This means buying IBM stock does not provide investors with direct access to upside from commercialized quantum AI. The subsidiary structure effectively insulates IBM from operating losses that come with developing quantum systems.
Among the pure-play quantum companies, the public names are D-Wave, Rigetti, and Infleqtion. The remaining four -- Atom Computing, Diraq, PsiQuantum, and Quantinuum -- are currently private.
That said, Quantinuum is not completely out of reach. The company recently filed an S-1 with the Securities and Exchange Commission (SEC), suggesting an IPO could be on the horizon sooner rather than later.
Moreover, investors have several options to gain passive exposure to Quantinuum. The company is majority-owned by Honeywell (HON +6.43%); meanwhile, Nvidia (NVDA +2.30%) participated in Quantinuum's $600 million funding round back in September. Buying shares of Honeywell or Nvidia quietly puts a portion of your portfolio in the quantum opportunity.
Are quantum computing stocks good buys right now? In my eyes, the honest answer about whether quantum computing stocks are good buys is that they can be, but investors need to be selective and measure appropriate risk tolerance.
Each of the pure-play public names jumped sharply on the funding announcement. This means that some good news is already priced in. The funding from the CHIPS Act should help reduce near-term capital risk and extend development runways. However, D-Wave, Rigetti, and Infleqtion are still early-stage businesses operating in a capital-intensive sector where commercial timelines are measured in years.
RGTI data by YCharts
For investors with a long-term horizon and who are comfortable with volatility, any pullbacks that follow announcement spikes are better entry points than chasing momentum right now. For those who prefer a lower-risk angle, Honeywell, Nvidia, and IBM still offer diversified, compelling ways to ride the quantum computing wave without getting overextended.
Quantum stocks are back, it seems, and D-Wave Quantum (QBTS +2.58%) is no exception. Shares of the quantum "pure play" are up 109% in the last two months.
A broader market rally has helped -- the S&P 500 is up 15.6% in the last month, the Nasdaq Composite is up 23.8% -- but some key catalysts have renewed investor faith in the sector.
First, Nvidia announced Ising, a new family of open-source AI models designed to accelerate quantum computing research. And the U.S. Department of Commerce announced a new $2 billion quantum investment program. D-Wave will receive $100 million in federal funding.
Today's Change
(
2.58
%) $
0.60
Current Price
$
23.85
The stock is now sitting just shy of $30. Is now the time to buy? The catalysts are encouraging, certainly, but they don't fundamentally change the picture in my eyes.
At present, D-Wave's financials aren't great to say the least: $12.5 million in sales over the last 12 months and a more than $100 million normalized loss during the same period.
Image source: Getty Images.
Despite this, the company's market cap is now north of $11 billion. There is a massive amount of faith baked into the stock price. That can work if D-Wave makes some serious leaps forward soon in the development of its technology, but it's likely real commercial quantum is many years -- maybe decades -- away.
If, in that time, there is a major market correction, investors will flee speculative stocks like D-Wave, and its share price will plummet. I think there will be serious buying opportunities in the future, and I would avoid D-Wave right now.
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.
Employee-driven recognition highlights the strength of D-Wave’s culture of collaboration, innovation and purpose as the company advances the commercialization of quantum computing
PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that it has been awarded the Great Place To Work Certification™ for 2026. The recognition is based entirely on employee feedback and reflects the strength of D-Wave’s culture during a period of rapid growth and innovation, as the Company continues to expand the team advancing the commercialization of quantum computing.
Great Place To Work is regarded as a global authority on workplace culture, employee experience and leadership behaviors proven to help organizations build high-performing workplaces. The certification is awarded based entirely on employee survey results evaluating trust, respect, credibility, fairness, pride and camaraderie within the workplace.
This recognition comes at a time of continued momentum for D-Wave, as the Company scales its global workforce and intensifies its work with enterprises, research institutions and government organizations seeking to apply quantum computing to complex business and scientific challenges.
“At D-Wave, our culture is built by extraordinary people who are solving hard problems, building breakthrough technologies and helping create the market for quantum computing,” said Dr. Alan Baratz, CEO of D-Wave. “This certification is especially meaningful because it reflects the voices and experiences of our employees. As we continue to grow rapidly, maintaining the culture that enables our people to do their best work is both a priority and a remarkable achievement.”
A Great Place To Work Certification is recognized worldwide by employees and employers alike and is considered the global benchmark for identifying and recognizing outstanding employee experience.
To explore careers at D-Wave, visit: https://www.dwavequantum.com/careers/
About Great Place To Work®
As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
About D-Wave Quantum Inc.
D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. It is the world’s first commercial supplier of quantum computers, and the first and only to offer dual-platform quantum computing products and services, spanning both annealing and gate-model quantum computing technologies. D-Wave’s mission is to help customers realize the value of quantum today through enterprise-grade systems available on-premises and via its Leap™ quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations across commercial, government and research sectors trust D-Wave to address complex computational challenges using quantum computing. Learn more about realizing the value of quantum computing today and how D-Wave is shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.
Key Takeaways D-Wave targets 100 logical qubits by 2032, capable of performing more than 1 million operations.QBTS plans systems in 2026, 2027 and 2028 with progressively larger error reduction factors.D-Wave says dual-rail qubits can detect about 90% of errors and achieved 99.9% two-qubit fidelities. D-Wave Quantum (QBTS - Free Report) or D-Wave is advancing its push toward commercial, fault-tolerant quantum computing. The company recently laid out a new gate-model roadmap, targeting 100 logical qubits capable of successfully performing over 1 million operations by 2032. The strategy builds on D-Wave’s expertise in high-coherence dual-rail qubits and quantum error correction, while leveraging its expertise in scaling and commercializing superconducting quantum systems.
At its first Investor Day on June 1, the company detailed a series of technical milestones underpinning this roadmap, including a 17-physical-qubit system in 2026 that supports logical error rates two times lower than physical error rates. D-Wave also expects to complete a 49-physical-qubit system in 2027, capable of a 20-fold error reduction factor and a 181-physical-qubit system in 2028 that can deliver a 2,000-fold error reduction factor.
Unlike many industry peers that focus on scaling physical qubits, D-Wave is pursuing an approach centered on reducing errors at the hardware level. Its dual-rail qubit architecture incorporates error detection directly into the qubits, allowing errors to be detected during computation at the single-qubit level.
According to D-Wave, its dual-rail qubits can identify approximately 90% of errors as they occur, helping reduce the number of physical qubits required to perform error correction. This is in contrast to many other gate-model hardware modalities that cannot detect qubit errors. The company has also demonstrated 99.9% two-qubit fidelities with error detection, meaning physical errors occur only about one in every 1,000 operations.
Also, the roadmap calls for achieving a Lambda of 10, which D-Wave expects will reduce errors by a factor of 10 for each increment in error correction, making it possible to achieve fault-tolerant quantum computing with significantly fewer physical qubits.
What QBTS’ Peers Are Up To?IonQ (IONQ - Free Report) , last month, marked the commercial launch of Interferometric Synthetic Aperture Radar (InSAR) capabilities through its space missions line. The offering enables millimeter-precision ground deformation monitoring with fully automated tasking and data delivery, allowing customers to detect and track physical change on the Earth’s surface consistently, at a frequency and scale never previously available from a commercial SAR provider. IonQ’s InSAR solution removes manual coordination and long revisit intervals.
IBM (IBM - Free Report) has announced plans to invest more than $10 billion in quantum computing over the next five years, spanning research and development, capital expenditure, manufacturing scaling, ecosystem partnerships and M&A. Collectively, these areas are designed to speed up IBM's quantum roadmap beyond its goal of delivering the first large-scale, fault-tolerant quantum computer in 2029 and bolster U.S. quantum leadership.
QBTS Price Performance, Valuation & EstimatesOver the past three months, D-Wave shares have rallied 47.4%, well ahead of the industry’s 3.6% growth.
Image Source: Zacks Investment Research
In terms of valuation, D-Wave is trading at a forward two-year Price/Sales (P/S) of 164.19X, significantly above its median and industry average.
Image Source: Zacks Investment Research
Estimates for D-Wave’s full-year 2026 and 2027 earnings are showing a mixed trend over the past 90 days.
Image Source: Zacks Investment Research
D-Wave currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
D-Wave Quantum stock is feeling bearish pressure. What’s weighing on QBTS shares? What Is Driving D-Wave Quantum’s Recent Performance?At a recent Investor Day, D-Wave highlighted a two-year, $10 million Quantum Compute-as-a-Service agreement with a Fortune 100 customer, with CEO Alan Baratz saying the customer has moved its first application "in production" and is running it daily. CFO John Markovich also said the company's four production systems imply about $100 million to $120 million of annual QCaaS revenue capacity on the Leap cloud platform.
D-Wave also has a longer-dated catalyst stack tied to federal support: a Letter of Intent signed 11 days before its Investor Day would invest $100 million under the CHIPS Act, with the Department of Commerce set to receive a minority, non-controlling equity stake.
Management paired that backdrop with a gate-model roadmap targeting 100 logical qubits and more than one million operations by 2032, built on a superconducting dual-rail architecture that detects about 90% of single-qubit errors.
Critical Price Levels To Watch For QBTSFrom a trend perspective, QBTS is still holding a constructive intermediate setup: it's trading 22.5% above its 50-day SMA ($20.51) and 7.2% above its 200-day SMA ($23.42), which keeps the bigger picture tilted upward despite today's drop. Near-term, it's only 1.3% above the 20-day SMA ($24.79) and slightly below the 20-day EMA ($25.48), so the stock is testing whether the latest momentum leg can stay intact.
Momentum-wise, MACD is above its signal line with a positive histogram, which points to improving upside pressure versus the prior downswing even if price is choppy day-to-day. The main technical "tug of war" is that the 20-day SMA is above the 50-day SMA (bullish), but the death cross from March (50-day below the 200-day) is still a longer-term caution flag that rallies can remain volatile.
Key Resistance: $29.00 — a round-number area that can act as a nearby ceiling after sharp swings Key Support: $23.50 — a nearby floor that sits close to the 200-day SMA zone, where dip-buyers often look for confirmation What Is D-Wave Quantum And Its Business Model?D-Wave Quantum is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers.
It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling.
D-Wave Quantum Stock Price Movement TodayQBTS Stock Price Activity: D-Wave Quantum shares were down 8.61% at $25.26 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
IonQ (IONQ +2.67%) is battling D-Wave (QBTS +2.58%) and Rigetti (RGTI +6.51%) in one of the strangest quantum stock setups on the market. The stocks look damaged, but the businesses tell a more complicated story, with revenue growth, government contracts, acquisition potential, and major technology risk all colliding at once.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends IonQ. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
I've got bad news and good news for D-Wave Quantum (QBTS +2.58%) investors today.
Bad news first: D-Wave stock is plunging 11% through 11:45 a.m. ET Friday. And the good news?
Image source: Getty Images.
No bad news for D-Wave stock The good news is that there's no specific bad news behind the sell-off -- no earnings reports that missed targets, no analyst downgrades, not so much as a lowered price target on Wall Street. Instead, D-Wave stock seems to be crashing simply because everything tech is selling off today: Nvidia (NVDA +2.30%) shares are off nearly 5% this morning, and Bitcoin (BTC +2.62%) is down more than 5%. Red-hot memory company Micron (MU +11.48%) has already lost 7%.
Basically, what we're looking at here is just a "risk-off" day for the market.
What sparked it? The most likely catalyst stems from worries over Broadcom's (AVGO +3.55%) earnings report Wednesday night. Broadcom spooked investors when it warned that sales of its artificial intelligence chips will "only" triple in Q3, and not grow even faster, as analysts had hoped.
And now everyone is panicking about everything tech, quantum computing stocks included.
Today's Change
(
2.58
%) $
0.60
Current Price
$
23.85
So, is it safe to buy D-Wave stock? Just knowing why D-Wave stock is selling off doesn't necessarily mean it's safe to buy it, however. As a technology and as an industry, quantum computing is still in its infancy and probably years away from being a profitable endeavor.
In the case of D-Wave, analysts polled by S&P Global Market Intelligence don't expect profits to arrive as far out as analysts are willing to make forecasts (in D-Wave's case, that's 2030). Worse, D-Wave will probably burn through more than $500 million in cash before it turns profitable. Before buying today's dip, make sure to check your risk tolerance first.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Broadcom, Micron Technology, and Nvidia. The Motley Fool has a disclosure policy.
Quantinuum, the Honeywell-backed trapped-ion quantum computing company, began trading on the NASDAQ today after pricing its IPO at $60 per share and raising $1.68 billion. On CNBC’s Squawk Box this morning, CEO Rajeeb Hazra delivered the line that will define the debut: “It is not 10 to 15 years out. It’s very much now. And we will only see acceleration going forward.”
That is a bold framing on a day when investors are also digesting the company’s early-stage financials. It is also a direct challenge to the long-running skeptic view that quantum is still a science project.
The Debut Quantinuum was spun out of Honeywell, which remains a majority shareholder post-IPO. The company builds trapped-ion quantum computers, including hardware called Helios. Trapped-ion systems use charged atoms held in electromagnetic fields as qubits, an approach valued for high gate fidelity and accuracy. It is the same broad architecture used by IonQ (NYSE:IONQ | IONQ Price Prediction), making IonQ the closest public comparable for investors trying to triangulate Quantinuum’s positioning.
The “Very Much Now” Thesis Hazra’s pitch leans on customers rather than theory. “We have customers today that are using our commercially available hardware and software, our full stack, to get started with their quantum journey on transforming, whether it’s their product set is pharma, their product set is financial instruments, their product set is new chemicals,” he said. He also tied quantum directly to the AI buildout: “We are in a transformative moment for the computing industry as AI and workloads take over and drive increasing amounts of value.”
He acknowledged the stage of the market, calling it “early days of a massive industry,” where the KPIs are hardware performance and accuracy.
The Profitability Question Here is where investors will scrutinize the story. Quantinuum reported 2025 revenue of $31 million and 2025 bookings of $79 million, but Q1 2026 revenue was only $1.3 million. The gap between booked commitments and recognized revenue is the central tension. Lumpy revenue is typical for pre-mass-commercialization deep tech, and the public comps show the same pattern in different forms. IonQ posted Q1 FY26 revenue of $64.67M, up 755% YoY, while D-Wave Quantum (NYSE:QBTS) reported Q1 FY26 revenue of $2.86M, down 81% YoY against a tough prior-year system-sale comp.
Government Validation and the Quantum IPO Wave Hazra confirmed Quantinuum has signed a Department of Commerce LOI: “This R&D grant is intended to allow us to be able to scale those technologies, including supply chain onshore in the US.” That ties into a broader theme. The Commerce Department’s $2 billion quantum initiative, announced May 21, 2026, included $100 million planned for D-Wave, $100 million for Quantinuum, and up to $100 million for Rigetti. Washington is treating quantum as strategic infrastructure.
For investors who want exposure today, the public comps are the established route. IonQ trades at roughly a $26.65 billion market cap with a P/E of 183 and an analyst consensus target of $67.64 ( 11 Buy, 2 Hold, 0 Sell). Polymarket assigns a 53.5% probability that the US federal government takes a stake in IonQ by year-end.
D-Wave runs both annealing and gate-model systems and is up 31.69% over the past month. Rigetti Computing (NASDAQ:RGTI) pursues superconducting chiplet architecture and has gained 100.12% over the past year. These are different architectures with different risk profiles, not equivalents to Quantinuum. For deeper background on how the architectures compare, see our coverage of the D-Wave vs. IonQ matchup.
The Takeaway Quantinuum’s listing is a real milestone. A well-funded, Honeywell-backed, government-validated trapped-ion company is now public, and its CEO insists the commercial era has started. The number to watch is the conversion of bookings into recognized revenue. CEO Hazra is asking investors to believe in acceleration. The financials say it is still early days. Quantum is moving from lab to market, and investors should size positions with that distinction in mind.
D-Wave Quantum (QBTS +2.58%) stock got hit with a substantial valuation contraction on Tuesday amid bearish momentum for the broader market. The company's share price ended the day down 8.9% in a session that saw the S&P 500's level decline by 0.3% and the Nasdaq Composite's level fall by 1%. Selling pressures had actually been far stronger earlier in the session, and D-Wave had been down as much as 13.5% at one point in the day.
The broader market fell in response to multiple catalysts today. For starters, investor confidence in the artificial intelligence trade is showing some signs of softening after what has otherwise been a strong bullish backdrop in 2026. Investors are also feeling jittery ahead of the Consumer Price Index (CPI) report from the Bureau of Labor Statistics that could play a big role in determining the Federal Reserve's next moves on interest rates. Anxieties surrounding the potential market-moving impact of SpaceX's initial public offering this coming Friday also pushed stocks lower.
Image source: Getty Images.
Is D-Wave stock a buy on today's pullback? Following today's pullback, D-Wave now has a market capitalization of $8.8 billion. Meanwhile, the company is valued at approximately 207 times this year's expected sales. Given the potentially revolutionary implications of D-Wave's quantum computing technologies, the stock is a difficult one to value -- but its high price-to-sales ratio shows that some very strong growth is already being priced into the company's valuation.
Today's Change
(
2.58
%) $
0.60
Current Price
$
23.85
Today's pullback hasn't done much to alter the fundamental outlook for D-Wave. While the stock looks meaningfully cheaper following the sell-off, investors are still probably looking at a binary outcome when it comes to whether a long-term investment would be explosively successful or result in the lost of most or all of your principal investment. I wouldn't try to aggressively dissuade anyone from investing in the potentially explosive stock, but I think even strong quantum bulls may be able to wait for a bigger pullback.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Last month, the U.S. government announced it would take stakes in a handful of quantum computing companies, including D-Wave Quantum (QBTS +2.58%) and Rigetti Computing (RGTI +6.51%). Both will receive up to $100 million in equity investment.
It has historically been rare for the U.S. government to take equity stakes in companies, with it generally happening during periods of severe economic distress. The government would also generally divest its stake once the companies were healthy.
However, the Trump administration has been more proactive with investments, instead looking to form partnerships in the interest of national security and to reduce reliance on foreign competitors. An earlier investment in Intel proved to be very fortuitous, as the stock has since skyrocketed. Meanwhile, with quantum computing expected to be the next big technology after artificial intelligence (AI), it appears the U.S. government wants to have some control over what could become a world-altering technology.
The question, though, is whether the government's investment is a validation of quantum computing technology or just a speculative bet. Are Rigetti and D-Wave worth investing in? Let's take a closer look at the two stocks.
Image source: Getty Images.
Rigetti is set to get up to $100 million over three years to help support research and development to overcome some of the big technical challenges associated with advancing and scaling superconducting quantum computing. The company's superconducting technique has proven to be very fast, but it greatly trails in accuracy to other techniques like trapped-ion.
Today's Change
(
6.51
%) $
1.26
Current Price
$
20.71
That's the biggest issue facing the company and its technology at this time. It had to delay its new 108-qubit Cepheus-1-108Q system to improve its accuracy, and when it did release it, its 99.1% 2-qubit gate fidelity (accuracy) missed the 99.5% median 2-qubit gate fidelity it was shooting for at release. The company's technology also wasn't chosen to advance to Stage B of the Quantum Benchmarking Initiative (QBI) for the U.S. Defense Advanced Research Projects Agency (DARPA). This is a Pentagon-funded program to help find and support the best quantum computing technologies, so this was a big blow.
D-Wave Quantum D-Wave Quantum will get a $100 million investment to help accelerate the development of its annealing and gate-model quantum computing technologies, specifically its 100,000-qubit annealing system and a 10,000-qubit gate-model system.
Today's Change
(
2.58
%) $
0.60
Current Price
$
23.85
D-Wave is a leader in quantum annealing technology, which is a narrower, specialized technology that shines at solving optimization problems by settling on the best or close to the best answers for complex problems. The technology is further along than broad-based quantum computing, with the company already selling machines for commercial use to industries like finance, logistics, and defense.
However, annealing is not the big quantum computing riddle companies are trying to solve, and as such, D-Wave is looking to apply its annealing expertise to traditional gate-based quantum computers. With its acquisition of Quantum Circuits, it is now pursuing a dual-rail qubit architecture, which it says will have the fidelity of the trapped-ion technology with the speed of superconducting qubits. However, it has not released any technical milestones yet that support this claim.
The verdict One notable thing about the investments the government made is that they are spread among companies pursuing quantum computing in very distinct ways. Rigetti, for instance, is taking a traditional superconducting approach, while D-Wave is pursuing a dual-rail qubit architecture based on its leadership in quantum annealing. Meanwhile, the government is also investing in Infleqtion (INFQ +4.42%), which uses a neutral-atom approach to quantum computing, and Quantinuum (QNT +9.90%), which is pursuing trapped-ion technology.
Overall, the government's investments look like a widespread bet on different competing quantum technologies and not really on individual stocks. As such, I wouldn't necessarily look at it as a validation of the stocks. I'd continue to view both D-Wave and Rigetti as highly speculative at this point, and actually prefer stocks pursuing trapped-ion technology, like IonQ (IONQ +2.67%) and Quantinuum, given the technology's accuracy edge. IonQ has achieved 99.99% 2-qubit gate fidelity, and Quantinuum 99.92%, giving them a distinct advantage in this area.
D-Wave Quantum (NYSE:QBTS) came public through a SPAC merger in August 2022 as a niche pioneer in quantum annealing, a narrower approach than the gate-model systems that dominate headlines. For its first two years on the tape, the story was patient commercialization: signing Forbes Global 2000 customers, shipping the Advantage2 platform, and burning cash while the rest of the quantum sector chased qubits.
The pivot came in 2025-2026. D-Wave acquired Quantum Circuits, Inc., adding dual-rail superconducting qubits with gate fidelities exceeding 99.9%, and now markets itself as the only player pursuing both annealing and gate-model systems. CEO Alan Baratz laid out a roadmap targeting 1,000 physical qubits with 10 logical qubits by 2030 and a 100,000-qubit Advantage3 annealing machine. FY2025 revenue hit $24.59 million, up 178.54% YoY, and Q1 2026 bookings rocketed to $33.40 million.
Your $1,000 at IPO Is Now $2,352 D-Wave has only traded publicly since August 2022, so the available history covers roughly four years.
1-Year Return
Initial Investment: $1,000 Current Value: $1,310.30 Total Return: 31.03% S&P 500 (same period): $1,229.10 (22.91%) Since IPO (August 2022)
Initial Investment: $1,000 Current Value: $2,352 Total Return: 135.2% S&P 500 (same period): $1,779.60 (77.96%) That headline number hides a brutal ride. QBTS opened near $10, sank into the low single digits during 2023, then ripped to a 52-week high of $46.75 before settling at $23.52. Holders who bought at IPO and never flinched doubled their money and beat the S&P. Anyone who chased the recent top is down meaningfully, including a 21.36% drop just this past week. Timing mattered enormously here.
The Case For and Against Putting $1,000 In Today I’d put $1,000 into D-Wave today if I believe quantum computing reaches commercial scale this decade and that owning the only dual-platform pure-play is worth a price-to-sales ratio of roughly 710. The bull case rests on bookings up roughly 2,000% YoY, a $588 million cash pile, defense traction with Anduril and Davidson Technologies, and analyst targets sitting at $36.44.
I’d avoid it if I cannot stomach $45 million in quarterly operating cash burn, a share count that ballooned from 266.6 million to 358.7 million, and revenue that swung down 81% YoY in Q1 on one missing system sale. The gate-model roadmap stretches to 2032 for meaningful logical qubits, and competitors are not standing still.
Personally, I lean toward a small starter position rather than a full $1,000. The technology story is real, but at a $8.84 billion market cap on $12.4 million in trailing revenue, you are paying for a future that may take six more years to arrive.
There was a time when the quantum computing investment thesis was more hype than anything. That was enough to tempt some retail investors for a while. However, markets eventually graduated to the “show me” stage. That put a burden on listed quantum computing companies to deliver tangible results.
Signs of progress are emerging, including the U.S. government recently announcing it will dole out $2 billion to nine companies in this industry. That confirms the U.S. views quantum computing as a critical industry in which it wants to lead — and that it’s willing to finance that objective.
The WisdomTree Artificial Intelligence and Innovation Fund (WQTM), which debuted last October, benefited from that announcement. The ETF is higher by nearly 13% over the past month. Some of its holdings, including International Business Machines (IBM), are among the companies enjoy Uncle Sam’s quantum spoils. While that’s a credible catalyst, it’s not the only reason WQTM merits consideration by tactical technology investors.
When Purity Matters, Consider WQTM Considering the relative youth of the quantum computing investment thesis, advisors and investors have a decent number of ETFs, including WQTM, from which to choose. However, the WisdomTree ETF stands out because of its emphasis on quantum computing purity.
Many of its holdings can be considered pure-play quantum stocks, or close to it. Some of the other ETFs in the category, meanwhile, allocate heavily to larger tech companies, with small exposure to quantum computing.
Take, for example, the pure quantum name IonQ (IONQ), WQTM’s third-largest holding. That company is about two months removed from a marquee milestone, it announced on World Quantum Day.
“By linking two commercial trapped-ion systems via quantum entanglement, IonQ demonstrated that its platform can participate in distributed, modular quantum computing, the design pattern that most serious roadmaps require at scale,” noted WisdomTree’s Christopher Gannatti. “The quantum memory technology enabling that link, fabricated from synthetic diamond, came through IonQ’s 2024 acquisition of Lightsynq.”
Rigetti Computing (RGTI), WQTM’s second-largest component, is another example of a pure-play quantum name, with bellwether status in the group. In revenue terms, this is an early-stage company. If it makes progress on superconducting chiplets, though, it could be a key driver of long-term upside for WQTM.
D-Wave Quantum (QBTS), Infleqtion (INFQ), and Xanadu Quantum (XNDU), which combine for more than 11% of the WQTM roster, were also among the stocks with quantum purity mentioned by Gannatti in a recent note.
For more news, information, and analysis, visit the Modern Alpha Content Hub.
Disclosures This article was prepared as part of WisdomTree’s general paid sponsorship of VettaFi | ETF Trends. This specific content within and any opinions expressed therein belong solely to VettaFi and do not reflect the opinion or analysis of WisdomTree, its employees, or its affiliates. Content published on VettaFi | ETF Trends is provided for educational purposes only and should not be considered investment or tax advice. For investment or tax advice, please consult a financial professional.
WisdomTree is an independent company, unaffiliated with VettaFi | ETF Trends. WisdomTree has not been involved with the preparation of the content supplied by VettaFi | ETF Trends. It does not guarantee, or assume any responsibility for its content.
It has been about a month since the last earnings report for D-Wave Quantum Inc. (QBTS - Free Report) . Shares have added about 8.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is D-WAVE QUANTUM due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for D-Wave Quantum Inc. before we dive into how investors and analysts have reacted as of late.
D-Wave Q1 Earnings Beat, Revenues MissD-Wave posted a first-quarter 2026 loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 8 cents. The reported figure widened from a loss of 2 cents in the year-ago quarter.
Revenues came in at $2.86 million, down 80.9% year over year and below the consensus estimate of $5.01 million by 42.9%. Still, contract activity improved, with remaining performance obligations rising to $42.4 million at quarter-end.
Tough Comparison After Prior-Year System SaleThe quarter’s revenue decline was largely tied to a difficult comparison versus the first quarter of 2025 when the company recognized $12.6 million from its first annealing quantum computing system sale. Without a similar system revenue event, D-Wave delivered a smaller top line despite continued commercial engagement.
Management emphasized expanding adoption across both its annealing and gate-model platforms. During the quarter, D-Wave recognized revenues from more than 100 individual customers, with more than half classified as commercial enterprises, underscoring that demand remains broad, even as revenue recognition timing can be lumpy.
Scales Commercial Activity With Record BookingsD-Wave reported first-quarter 2026 bookings of $33.4 million, up 1,994% year over year and 149% higher than the prior quarter. The total included a $20 million system purchase agreement with Florida Atlantic University and a $10 million, two-year enterprise quantum computing as a service deal with a Fortune 100 customer.
Remaining performance obligations totaled $42.4 million as of March 31, 2026, with about 54% expected to be recognized as revenues over the next 12 months and 71% over the next two years, leaving a longer-duration tail beyond that.
Expands Platform Breadth With Quantum Circuits DealIn January 2026, D-Wave acquired Quantum Circuits, a developer of error-corrected superconducting gate-model systems. The company also laid out targeted roadmap milestones, including a dual-rail system with roughly 175 physical qubits by the end of 2028 and a 1,000 physical-qubit dual-rail system with 10 logical qubits by the end of 2030. D-Wave plans to provide additional details on its Investor Day at the New York Stock Exchange on June 1, 2026.
Profitability Metrics Show Margin CompressionOn a non-GAAP basis, gross profit was $2.0 million, down 86% from the prior-year quarter. The corresponding non-GAAP gross margin was 70.6%, down 2300 basis points (bps) year over year, reflecting a different revenue mix versus the year-ago period that benefited from a system sale.
Operating discipline also remained in focus as investments ramped up. Non-GAAP adjusted operating expenses were $34.8 million, up 73% year over year, while adjusted EBITDA loss widened to $32.8 million. Management attributed higher spending to initiatives supporting accelerated product development and go-to-market execution, along with costs incurred following the Quantum Circuits acquisition.
Liquidity Remains Strong After Large Investing OutflowQBTS ended the quarter with $588.4 million in cash and marketable investment securities, up 93% year over year. The balance sheet strength provides flexibility as the company funds product development, go-to-market initiatives and integration work following the Quantum Circuits acquisition.
Cash flow reflected that investment posture. Net cash used in operating activities was $45.0 million, while net cash used in investing activities totaled $252.1 million, driven primarily by acquisition-related cash outflows. Despite the heavier spend, management framed liquidity as a key support for executing its dual-platform strategy in a rapidly evolving quantum computing market.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -11.29% due to these changes.
VGM ScoresCurrently, D-WAVE QUANTUM has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a score of F on the value side, putting it in the lowest quintile for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, D-WAVE QUANTUM has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerD-WAVE QUANTUM is part of the Zacks Internet - Software industry. Over the past month, Broadridge Financial Solutions (BR - Free Report) , a stock from the same industry, has gained 1.7%. The company reported its results for the quarter ended March 2026 more than a month ago.
Broadridge Financial reported revenues of $1.95 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $2.72 for the same period compares with $2.44 a year ago.
For the current quarter, Broadridge Financial is expected to post earnings of $3.76 per share, indicating a change of +5.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Broadridge Financial. Also, the stock has a VGM Score of B.
Key Takeaways Quantinuum stock fell about 15% in a week after its record pure-play quantum computing IPO.Quantinuum raised $600M privately and $1.68B in its IPO, boosting its capital base.Quantinuum had $30.9M in 2025 revenues and incurred a roughly $193M net loss. Honeywell owns about 48%. Seven days after completing the largest pure-play quantum computing IPO on record, Honeywell (HON - Free Report) -backed Quantinuum's (QNT - Free Report) stock has lost roughly 15% of its value, falling from its $60 IPO price to around $51. The decline suggests that the market is moving beyond IPO enthusiasm and beginning to assess whether the company's long-term growth prospects justify its valuation.
For investors, this may be the right time to reassess the opportunity and determine whether the recent pullback offers an attractive entry point or signals a need for caution.
Image Source: Zacks Investment Research
How Quantinuum Compares With IonQ and D-WaveMore importantly, can Quantinuum replicate the wealth-creating trajectories witnessed in quantum computing leaders such as IonQ (IONQ - Free Report) and D-Wave Quantum (QBTS - Free Report) , or does its current valuation already reflect much of its future potential? Investors must now look beyond the post-IPO price action and assess whether Quantinuum's technological leadership and progress in commercialization are sufficient to justify its multi-billion-dollar valuation.
Like Quantinuum, both IONQ and QBTS stocks experienced significant volatility after going public. While D-Wave's shares struggled for an extended period before surging on renewed enthusiasm for quantum computing applications, IonQ gradually gained its position as the sector's benchmark through consistent technological progress, expanding customer relationships and growing commercial bookings.
Quantinuum, however, enters the public markets with advantages that neither IonQ nor D-Wave possessed at listing. Honeywell retains an approximately 48% stake in the company, providing strategic backing and financial stability.
Strong Capital Base Supports Long-Term Growth OutlookBeyond its technology, Quantinuum's capital position is perhaps one of its biggest competitive advantages. The company raised approximately $600 million in a private funding round in September 2025 at a $10 billion pre-money valuation, attracting investors like NVentures, JPMorganChase and Amgen. It then raised an additional $1.68 billion through its June 2026 IPO, giving it one of the strongest balance sheets among publicly traded quantum computing companies. The funding is expected to support continued technology development, commercialization efforts and the company's long-term goal of achieving universal fault-tolerant quantum computing.
Quantinuum also benefits from Honeywell's continued ownership stake and a growing ecosystem of strategic partnerships spanning NVIDIA, RIKEN, SoftBank and others. Unlike many emerging quantum companies that may eventually require additional financing to sustain operations, Quantinuum appears well-capitalized to execute its roadmap. The key challenge now is not access to capital, but converting its technological leadership and industry relationships into sustained revenue growth and broader commercial adoption.
Final TakeUnlike many emerging quantum computing companies that may eventually require additional financing to sustain operations, Quantinuum appears well-capitalized to execute its roadmap. However, investors should not overlook the valuation challenge. The company generated only $30.9 million in revenues in 2025 while reporting a net loss of roughly $193 million. As a result, the investment case ultimately hinges not on access to capital, but on Quantinuum's ability to translate its technological leadership, industry relationships and financial resources into sustained revenue growth and broader commercial adoption.
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence.
What This Collaboration Means for the Pharma Market
Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence’s platform enables precise definition of health data needs via Computable Operational Definitions (CODefs)—standardized, executable queries that translate complex study criteria (e.g., patient cohorts by diagnosis, treatment, or outcome) into consistent, computable form across datasets.
This collaboration integrates Navidence’s CODefs with the OneMedNet iRWD™ platform powered by Palantir Foundry.
Key integration elements of the collaboration include:
OneMedNet incorporating Navidence CODefs, to enable consistent cohort, endpoint, and criteria definitions.Navidence being integrated with the OneMedNet iRWD™ platform for life sciences, to enable rapid discovery of fit-for-purpose multimodal datasets, streamlining study design regulatory / commercial evidence generation. Key Potential Benefits of the Collaboration to Our Products and Stakeholders
Efficiency Gains: Align CODefs with available RWD in near real-time to accelerate study ideation-to-execution and reduce mismatches / rework.Cost Savings: Expected to enable precise data matching to avoid over-procuring data sets or pursuing infeasible studies, optimizing R&D budgets.Regulatory and Compliance Edge: Combine OneMedNet’s de-identification expertise and Navidence’s standardized definitions to better meet FDA, EMA, and payer requirements for RWE.Innovation in Therapeutic Areas: Particularly valuable in complex fields like precision medicine, where imaging RWD (e.g., MRIs, CT scans) combined with CODefs can reveal nuanced insights into disease progression or treatment efficacy. Expanding Commercial Opportunity
Real-World Data has long been available, but missing efficient, standardized, and scalable access to Real-World Data.
This collaboration is intended to directly advance OneMedNet’s life sciences strategy by addressing core industry demands of faster, more precise and usable data for pharmaceutical and CRO customers, along with expanded opportunities in the rapidly growing RWD market (valued at approximately $1.88 billion in 2025 and projected to reach $6.37 billion by 2034 at 14.54% CAGR),1 enabling access to precisely defined, fit for purpose datasets across:
Drug development and Life sciences researchAI model training and validationHealth economics and outcomes research (HEOR)Regulatory-grade evidence generationValue-based healthcare analytics
As regulators and payers increasingly require robust real-world evidence, we believe that combining large-scale multimodal data infrastructure with computable definitions positions both companies—and their customers—at the forefront of data transformation.
“Healthcare organizations today have access to more data than ever before and turning that data into reliable evidence requires both scale and precision,” said Aaron Green, CEO & President of OneMedNet. “By combining OneMedNet’s multimodal real-world data platform with Navidence’s computable definitions, we can help researchers identify the right data faster and design studies that deliver high impact evidence.”
“Computable Operational Definitions (CODefs) provide the foundation for consistent and reproducible research independent of the data source,” said Aaron Kamauu, Navidence. “By integrating our content with the OneMedNet iRWD™ platform, researchers can discover precisely defined cohorts and datasets that accelerate study development and improve consistency across clinical research.”
https://www.precedenceresearch.com/real-world-data-rwd-market About Navidence Inc.
Navidence is a technology company that helps healthcare and life sciences organizations design and assess the use of real-world data in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data to support smarter research and better patient outcomes. To learn more about Navidence, visit www.navidence.com and follow us on LinkedIn.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies (including the expected benefits of the collaboration with Navidence), and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet’s iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.
Under the agreement, Inka Health is gaining access to OneMedNet’s iRWD™ platform through a selective pilot program following technical evaluation and qualification. The collaboration will initially focus on applying real-world data and advanced analytics to support Onco’s PNKP Inhibitor Technology’s development strategy, including patient responder identification, indication expansion beyond advanced metastatic colorectal cancer, and complementary evidence generation to inform clinical and regulatory decision-making. Inka Health also intends to use OneMedNet’s iRWD™ platform to improve and further develop the core model of SynoGraph™, its causal-inference based AI platform that aims to predict the success and safety of potential new cancer treatments by analyzing multimodal medical data.
Importantly, this engagement reflects the original architectural intent of the iRWD™ platform: to enable rapid identification and characterization of rare and molecularly defined patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, —such as PTEN/SHP1-deficient tumors—, and accelerate innovation in areas where traditional trial recruitment and evidence development can be challenging.
“This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high-value patient populations to accelerate innovation,” said Aaron Green, CEO & President of OneMedNet. “By bringing together regulatory-grade real-world data, multi-modal clinical depth, and Palantir-powered AI, we can help oncology innovators de-risk development, move faster, and generate meaningful evidence in complex disease segments.”
“Access to high-quality U.S. oncology real-world data is a critical enabler for PNKP Inhibitor Technology,” said Thomas O’Shaunghnessy, CEO of Onco-Innovations. “This collaboration allows us to better understand real-world patient populations with PTEN/SHP1-deficient tumors, identify potential responders, and explore additional indications—, helping us de-risk development while improving capital efficiency for shareholders.”
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet’s rapidly growing network.
2025 Financial Highlights:
RWD Revenue Growth: RWD revenue increased 329% year-over-year, rising from $292,000 in 2024 to $1,254,000 in 2025, reflecting strong market demand and increased commercial traction. Fourth Quarter Revenue Acceleration: Our work towards building and executing upon our strategy came together during the quarter ended December 31, 2025 with revenue surging to over $890,000. Bookings Momentum: Revenue growth is beginning to align with previously disclosed increases in bookings, reinforcing the Company’s transition toward a scalable, subscription-based model. Total Liabilities Reduced by 74%: Total liabilities decreased from $19.7 million at December 31, 2024 to $5.1 million at December 31, 2025.Driven by a combination of negotiated settlements and debt-to-equity conversions. Equity Position Improved: Shareholder deficit substantially reduced from $(16.0) million to $(3.0) million.
Building upon next commercial phase momentum:
Following its February 2026 announcement, OneMedNet entered a new phase of commercial execution centered on its AI-driven iRWD™ platform powered by Palantir Foundry, with the following commercial highlights: 2 Pilot Customers in contracting.4 Additional customers expected in the second and third quarter of 2026, each representing a seven-figure subscription revenue potential over the term of the contract.Advanced stage pipeline of additional multi-year subscription opportunities. Early Verbal Customer Feedback of the OneMedNet Platform: Cohort discovery timelines reduced from weeks to minutes - Significant improvements in feasibility analysis and dataset precision.Ability to query over a billion data points with results returned in seconds. Platform Scale and Network Expansion Outlook: OneMedNet accelerates its provider network expansion and overall data scale, enabling the Company to fulfill additional orders and deliver greater value to subscription customers.Projected 4x growth in the platform by the end of 2026. “Our 2025 performance marks a pivotal turning point for OneMedNet,” said Aaron Green, CEO & President. “We have successfully sunset our BEAM solution along with the expenses associated with it, allowing us to focus fully on our Real-World Data business achieving meaningful revenue acceleration, dramatically improving our balance sheet, and launching the next generation of our platform. We believe the early response from customers validates our strategy — delivering real-world data with the speed, scale, and intelligence required to power modern healthcare innovation. Looking ahead to 2026, we will continue to build and execute on this strategy and expect revenues to grow substantially.”
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed.
Key Commercial Milestones of iRWD™ Platform:
OneMedNet iRWD™ Platform Now Live on Palantir Foundry~70% increase in OneMedNet network, to 80 million patients and 251 million studies Creating what we believe is the industry's largest network of curated, multi-modal Real-World Data Creates access to approximately 47 million tokenized patients via Datavant Enables seamless linkage to complementary datasets including genomics, claims, and mortality data for deeper longitudinal insights Two new customers contracted for iRWD™ Platform "The integration of our iRWD™ platform with Palantir Foundry marks a transformative step for OneMedNet. Our subscription customers can now find the data they need in seconds — unlocking a new phase of commercial execution and significantly enhancing our ability to deliver high-value, decision-grade data. We are now actively converting a robust pipeline into subscription-based customers with meaningful annual recurring revenue potential." said Aaron Green, President & CEO of OneMedNet. "Most importantly, we've unlocked the patients our customers require: about 80 million patients on the network and 47 million tokenized patients on Datavant. We previously outlined this strategy, and we've now executed on it. By combining Palantir's powerful ontology and analytics capabilities with Datavant's tokenized linkage, we can deliver longitudinally connected, multimodal datasets that accelerate foundational AI model development and create durable, long-term value."
With the Palantir-powered iRWD™ platform now live and fully searchable, OneMedNet is executing its strategy of securing high-margin, annual recurring revenue (ARR) subscriptions. The Company believes the combination of the new platform capabilities and an expanding customer pipeline positions the Company to convert growing interest into meaningful revenue opportunities.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the expected benefits and demand to be driven by the integration of the completed iRWD™ platform, and statements generally about our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
OneMedNet Corporation (NASDAQ:ONMD – Get Free Report) Director Thomas Kosasa purchased 280,898 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $0.89 per share, with a total value of $249,999.22. Following the completion of the transaction, the director owned 16,661,327 shares in the company, valued at approximately $14,828,581.03. This trade represents a 1.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Thomas Kosasa also recently made the following trade(s):
On Friday, February 6th, Thomas Kosasa purchased 595,238 shares of OneMedNet stock. The stock was acquired at an average price of $0.84 per share, with a total value of $499,999.92. OneMedNet Price Performance Shares of NASDAQ ONMD opened at $1.10 on Monday. OneMedNet Corporation has a twelve month low of $0.31 and a twelve month high of $4.22. The firm has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $1.23. The company has a market capitalization of $57.42 million, a PE ratio of -15.71 and a beta of 1.16.
OneMedNet (NASDAQ:ONMD – Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.89 million for the quarter.
Analyst Upgrades and Downgrades Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OneMedNet in a report on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
Check Out Our Latest Research Report on OneMedNet
Hedge Funds Weigh In On OneMedNet Several hedge funds and other institutional investors have recently bought and sold shares of ONMD. Exencial Wealth Advisors LLC lifted its holdings in OneMedNet by 141.3% in the third quarter. Exencial Wealth Advisors LLC now owns 3,599,460 shares of the company’s stock valued at $3,923,000 after buying an additional 2,107,598 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in OneMedNet in the third quarter valued at $25,000. Correct Capital Wealth Management acquired a new stake in OneMedNet in the third quarter worth $4,910,000. HRT Financial LP acquired a new stake in OneMedNet in the fourth quarter worth $32,000. Finally, Jane Street Group LLC acquired a new stake in OneMedNet in the fourth quarter worth $119,000. Institutional investors and hedge funds own 0.95% of the company’s stock.
About OneMedNet (Get Free Report)
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.
Further Reading Five stocks we like better than OneMedNet
Receive News & Ratings for OneMedNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OneMedNet and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINENVIDIA Corporation $NVDA Stock Position Increased by Diversify Advisory Services LLC
NEXT HEADLINE »United Therapeutics (NASDAQ:UTHR) CFO Sells $209,609.40 in Stock
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation. Today's announcement reflects the team's disciplined execution against that commitment – extending the breadth, depth, and connectivity of the network to meet accelerating demand for Real-World Data and AI foundational models.
Key Milestones:
More than 90 million patient journeys, a 12.5% increase since April 2026 in just two months, with 270 million studies available.Expanded provider network by more than 30% in less than a year, growing from approximately 1,750 to more than 2,300 healthcare partner sites.Encompasses hard to find data such as rare diseases, oncology, cardiology, and beyond.Increased specialized multi-modal data coverage across Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records. “Surpassing 90 million patient journeys, 270 million studies, and 2,300 healthcare partner sites is exactly the kind of progress we told our shareholders to expect when we outlined our strategy at the end of 2025," said Aaron Green, President & CEO of OneMedNet. "Growing the network is a deliberate, central pillar of how we build durable value, and this milestone shows the team executing against that plan. Life sciences organizations, drug developers, and AI innovators increasingly require deeper, more diverse, and longitudinally connected datasets. By continuously expanding our provider partnerships and the breadth of our curated, multi-modal data, we are uniquely positioned to meet the needs of life sciences organizations, drug developers, and AI innovators — delivering durable, long-term value for our customers and shareholders."
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the achievement of our strategies, , and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has secured more than $3 million in new bookings to date for 2026 as of this announcement – surpassing the Company's total bookings for all of full-year 2025. The Company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026.
, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
As of the October 20, 2025 data cutoff, with a median follow-up of more than two years, the cadonilimab plus chemotherapy combination continued to deliver robust and durable survival benefits. Results were particularly strong in patients with locally advanced disease, where the median PFS reached 11.1 months and the median OS exceeded 23 months. Landmark survival rates in this group included a 12-month OS rate of 91.7% and a 24-month OS rate of 44.1%.
The cadonilimab regimen also provided strong tumor control across the overall study population. Of the patients evaluable for efficacy (95% had at least one post-baseline tumor assessment), the objective response rate (ORR) was 33.9% and the disease control rate (DCR) reached 96.4%. Response rates were similar between patients with locally advanced and metastatic disease, indicating consistent benefit across both subgroups.
No new safety signals were identified, and the overall safety profile of the cadonilimab combination remained favorable and manageable.
Cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy, having received marketing approval in 2022. In extensive real-world clinical practice and multiple Phase III studies, it has demonstrated clinically meaningful benefit across all patient populations regardless of PD-L1 expression status, addressing a significant unmet medical need and earning broad recognition from physicians and patients.
As a cornerstone therapy in the era of tumor immunotherapy 2.0, cadonilimab not only offers the significant advantage of clinical benefit across broad patient populations, but has also demonstrated important breakthrough potential in difficult-to-treat settings, including immunotherapy-refractory disease and immunologically "cold" tumors. Akeso is fully leveraging its global leadership in bispecific antibody development for oncology to continue addressing major unmet clinical needs and advancing transformative treatment options for patients with challenging cancers.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. The abstract is now available on the EHA Congress platform.
Ligufalimab is Akeso's proprietary next-generation humanized IgG4 anti-CD47 monoclonal antibody. The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naïve acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
The abstract data demonstrated that the ligufalimab-based triplet regimen delivered encouraging efficacy, with significant improvements in survival outcomes. The combination also showed a manageable safety profile, offering a potentially better-tolerated treatment option for this vulnerable patient population.
As of the November 2025 data cutoff, key findings included:
Deep and Durable Tumor Remission
The objective response rate (ORR) was 80.0% in the ligufalimab arm versus 66.7% in the control arm, with a composite complete remission (CRc) rate of 56.7% versus 53.3%. Among patients achieving CRc, the measurable residual disease (MRD) negativity rate was higher in the ligufalimab arm (46.7% versus 36.7%). Median duration of CRc was substantially longer in the ligufalimab arm at 10.4 months versus 6.5 months in the control arm. Encouraging Survival Benefit Trend
At a median follow-up of 8.84 months, median overall survival (mOS) in the ligufalimab arm was not yet reached, versus 8.3 months in the control arm. The 9-month overall survival rate was 78.7% in the ligufalimab arm versus 43.1% in the control arm; the 6-month OS rates were 83.3% versus 73.2%, respectively. Favorable Safety Profile With No New Safety Signals Observed
The incidence of overall treatment-emergent adverse events (TEAEs) and serious adverse events was comparable between treatment arms. The most common TEAEs were generally consistent with those expected in the context of AML and AZA+VEN therapy. Anemia occurred in 46.7% of patients in the ligufalimab arm versus 50.0% in the control arm. Notably, ligufalimab has already received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of AML. Akeso is advancing its ligufalimab clinical development programs at a globally competitive pace across both hematologic malignancies and solid tumors. Ligufalimab is also the first anti-CD47 monoclonal antibody worldwide to enter a registrational Phase III clinical trial in solid tumors.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These landmark findings will be featured in a Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Professor Shun Lu, Director of the Lung Cancer Center at Shanghai Chest Hospital and Principal Investigator of HARMONi-6, presented the data in an oral Plenary Session presentation.
This marks the first time a China-originated investigational oncology drug has been selected for the ASCO Plenary Session in the society's 61-year history. This moment is a definitive testament to the ivonescimab regimen's role in ushering cancer immunotherapy into the '2.0 Era'.
The HARMONi-6 study results were simultaneously published in The Lancet.
The HARMONi-6 study enrolled a total of 532 patients. Among them, approximately 63% had centrally located squamous tumors, 39.0% had PD-L1 TPS <1%, and 33.8% had multi-site metastases, liver metastases, or brain metastases. At the pre-specified interim analysis, as assessed by the Independent Data Monitoring Committee (IDMC), the study met its key secondary endpoint of overall survival (OS), demonstrating both clinically a meaningful and statistically significant benefit.
As of the data cutoff date of February 27, 2026, with a median follow-up of 21.36 months:
34% reduction in the risk of death - ivonescimab plus chemotherapy significantly prolonged OS
In the intent-to-treat (ITT) population, ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (HR=0.66 [95% CI: 0.50–0.87], P=0.0017(＜0.0049). Median OS was 27.9 months in the ivonescimab arm (the final death event in this arm caused the Kaplan-Meier curve to drop sharply to the median, thereby producing the mOS estimate) versus 23.7 months in the control arm. The 12-month OS rate was 78.9% with ivonescimab plus chemotherapy versus 72.2% in the control arm, and the 24-month OS rate was 64.7% versus 48.6%, respectively. The survival benefit continued to widen over time, reflecting a more durable and clinically meaningful long-term survival advantage. Consistent OS benefit across all prespecified subgroups
OS benefit with ivonescimab was observed consistently regardless of PD-L1 expression status: HR=0.68 in the PD-L1 TPS ≥1% subgroup and HR=0.64 in the TPS <1% subgroup; HR=0.67 in the PD-L1 TPS 1–49% subgroup and HR=0.64 in the TPS ≥50% subgroup. The OS benefit was also consistent across subgroups defined by metastatic burden: HR=0.47 in patients with ≥3 metastatic sites and HR=0.69 in those with liver metastases. Comparable subsequent anticancer therapy between the two arms
Proportions of patients in the two groups who subsequently received immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving targeted therapy: 12.4% vs 17.3%; proportions receiving ADC therapy: 4.5% vs 5.6%; proportions participating in other clinical trials: 0.8% vs 2.3%.
Favorable safety profile comparable to tislelizumab plus chemotherapy
Grade ≥3 treatment-related adverse events (TRAEs) occurred in 69.2% of patients in the ivonescimab arm and 58.9% in the control arm. Rates of adverse events leading to treatment discontinuation or death were similar between arms. At the prespecified interim analysis for progression-free survival (PFS), ivonescimab plus chemotherapy had already demonstrated a clinically meaningful and statistically significant improvement in PFS compared with tislelizumab plus chemotherapy, with a median PFS of 11.1 months versus 6.9 months (HR=0.60 [95% CI: 0.46–0.78], P＜0.0001).
Professor Shun Lu, Principal Investigator of HARMONi-6, Director of the Lung Cancer Center at Shanghai Chest Hospital and Tenured Professor:
"HARMONi-6 is the first global Phase III study in lung cancer to show statistically significant improvements in both OS and PFS compared with PD-1 plus chemotherapy. It is also the first in sq-NSCLC to achieve dual OS and PFS success through a pre-specified hypothesis test. The results significantly reduced the risk of death and disease progression, with consistent benefits across all subgroups, while enabling patients to maintain better quality of life for longer.
These strong head-to-head data redefine the gold standard for first-line sq-NSCLC treatment and fill a major clinical gap for anti-angiogenic therapy in this setting. We look forward to ivonescimab delivering broader benefits to patients worldwide as a next-generation immuno-oncology therapy."
Dr. Yu Xia, Founder, Chairwoman, President and CEO of Akeso:
"Today, we are thrilled to announce that ivonescimab plus chemotherapy has successfully challenged PD-1 plus chemotherapy, achieving both clinically meaningful and statistically significant improvements in overall survival (OS) and progression-free survival (PFS). We extend our sincere gratitude to all investigators, clinical teams, and patients who participated in this study. Thanks to their efforts, Chinese patients with advanced sq-NSCLC are the first to benefit from this innovative, safe, and highly effective global therapy.
Prior to ivonescimab, no therapy had successfully challenged the dominance of PD-1-based regimens in a head-to-head Phase III trial. Ivonescimab has already demonstrated dual OS and PFS benefits in EGFR-mutant non-squamous NSCLC after TKI failure, becoming the first immunotherapy approved in this setting. It has also shown superior PFS versus pembrolizumab monotherapy in first-line PD-L1-positive NSCLC. These results have generated strong global anticipation for next-generation therapies. Since its launch, ivonescimab has been widely adopted by clinicians and patients.
PD-1 plus chemotherapy is currently the most broadly used first-line regimen in oncology. Following our previous success versus pembrolizumab monotherapy, the HARMONi-6 study now demonstrates for the first time that ivonescimab plus chemotherapy can achieve dual superiority in both OS and PFS over PD-1 plus chemotherapy. This landmark result solidifies ivonescimab's position as a next-generation cornerstone of cancer immunotherapy.
The success of HARMONi-6 gives us even greater confidence to leverage global resources, fully unlock ivonescimab's potential, reshape treatment paradigms, and deliver more effective and safer solutions to patients worldwide."
Ivonescimab is currently being evaluated in more than 30 clinical settings across a wide range of tumors, including 15 Phase III trials, seven of which are head-to-head studies versus PD-1/PD-L1 therapies. The positive results from HARMONi-6 further strengthen its differentiated clinical profile. In partnership with Summit Therapeutics, Akeso remains fully committed to advancing the global development of ivonescimab to maximize its therapeutic benefit for patients worldwide.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
A man looks at a Patriot Advanced Capability (PAC-3) Missile Segment Enhancement (MSE) model by Lockheed Martin at an international military fair in Kielce, Poland September 7, 2017.... Purchase Licensing Rights, opens new tab Read more
April 10 (Reuters) - Lockheed Martin (LMT.N), opens new tab said on Friday the U.S. government awarded the defense giant a $4.7 billion preliminary contract to continue critical accelerated production of the Patriot interceptor missile.
The contract for the Patriot Advanced Capability-3 Missile Segment Enhancement (PAC-3 MSE) follows a seven-year agreement with the U.S. Department of Defense to more than triple its annual production, as countries respond to heightened geopolitical tensions.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
Trump has ordered the department to rename itself the Department of War, a change that will require action by Congress.
PAC-3 MSE is used in U.S. Army's primary high-to-medium range interceptor system and forms the backbone of U.S. and allied air defenses.
Supplies of the PAC‑3 MSE, which Ukraine relies on to defend its energy and military infrastructure from ballistic missiles, are strained after heavy use in the Gulf against Iranian strikes, with the production boost unlikely to ease shortages this year.
Earlier this year, the U.S. State Department approved the potential sale of the PAC-3 MSE and related equipment to Saudi Arabia for an estimated cost of $9 billion.
Reporting by Aatreyee Dasgupta in Bengaluru; Editing by Vijay Kishore
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Reshoring is the macroeconomic theme of the United States, bringing industrial capacity from Asia (specifically China) back home to North and South America. Some manufacturing will be done in the United States (e.g., semiconductors), while some will flow to other nations.
No country is better positioned to benefit from reshoring than Mexico. But how does one invest to take advantage of the potential economic boom south of the border? The answer may lie in the aviation sector and the publicly traded airport stocks in Mexico.
Image source: Getty Images.
Grupo Aeroportuario del Pacífico: Betting on Mexican tourism Unlike in the United States, the operators of Mexican airports are publicly traded companies, of which there are three. They don't own the airport but have long-term (generally 50-year) contracts that allow them to manage these assets for the government while splitting the profits.
Grupo Aeroportuario del Pacífico (PAC +3.79%) is one of Mexico's airport operators, focused on the Pacific region, with its largest airports being in Guadalajara, Los Cabos, Tijuana, and Puerto Vallarta. These cities have a mix of international tourism and industrial capacity, with Tijuana benefiting from a land bridge connecting to San Diego that allows residents to easily get on cheaper flights when visiting Mexico.
The stock is trading down 15% from its highs due to fears over recent cartel violence in Mexico, which seems to have subsided for the time being, as well as global concerns about rising oil prices and their potential impact on air travel demand.
Airport operators such as Grupo Pacifico make money as more passengers flow through their airports, along with government-allowed price increases. Over the long term, air traffic to Mexico has exploded because of international tourism, general economic growth in Mexico, and growing industrial capacity in places such as Guadalajara, which drives business travel.
NYSE: PACGrupo Aeroportuario Del PacíficoB. De C.v.
Today's Change
(
3.79
%) $
8.41
Current Price
$
230.15
Right now, the stock trades at a dividend yield of 3.5% and at 13 times its trailing EBITDA (earnings before interest, taxes, depreciation, and amortization). This is for a business that has grown its revenue by 286% over the past 10 years in U.S. dollar terms, despite a global pandemic in between. Unless you think Mexican tourism is going to fall apart overnight, now could be a great time to buy Grupo Pacifico stock.
Grupo Aeroportuario del Centro Norte: The reshoring focus The airport operator most focused on the reshoring theme is Grupo Aeroportuario del Centro Norte (OMAB +3.33%), which operates the Monterrey airport and a number of smaller regional airports across Mexico's North and Western regions.
Today's Change
(
3.33
%) $
3.19
Current Price
$
99.11
Monterrey is the wealthiest large city in Mexico and is closest to the United States. It has become wealthier than the average Mexican metro area because of its industrial might, with many companies around the world setting up shop there to ship goods to the United States. It even offers direct flights to Tokyo and Seoul to serve electronic manufacturing companies in the area.
It lacks the tourist charm, but Monterrey will benefit if the reshoring trend continues through the rest of this decade. Total passenger traffic grew 8.5% year over year in 2025, with Monterrey growing 15% and making up around half of passenger volume. Right now, the stock trades at a dividend yield of 4.2% and 11.5 times EBITDA, making it even cheaper than Grupo Pacifico.
Data by YCharts.
Should you buy Mexican airport stocks? If you have only invested in your home market, it might feel scary to buy a stock from a country like Mexico, where you have less understanding of the local culture and economy. This fear may be warranted for consumer goods, but airports are very similar, no matter which country you go to.
Currency risks are another factor that pops up, but they can be mitigated by increasing per-passenger fees and by international traffic and commercial revenue from tourism shops. As a monopoly, the Mexican government regulates airports and determines the prices inbound flights can charge, with Grupo Norte granted the right to increase prices by 38% over the next five years. That sounds like a good business to me.
Mexican airport stocks are well-positioned to deliver strong returns for shareholders over the next decade.
